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Abstract: Chirality is one of the major issues in pharmaceutical research and industry. Capillary elec-
trophoresis (CE) is an interesting alternative to the more frequently used chromatographic techniques
in the enantioseparation of pharmaceuticals, and is used for the determination of enantiomeric ratio,
enantiomeric purity, and in pharmacokinetic studies. Traditionally, optimization of CE methods is
performed using a univariate one factor at a time (OFAT) approach; however, this strategy does not
allow for the evaluation of interactions between experimental factors, which may result in ineffective
method development and optimization. In the last two decades, Design of Experiments (DoE) has
been frequently employed to better understand the multidimensional effects and interactions of the
input factors on the output responses of analytical CE methods. DoE can be divided into two types:
screening and optimization designs. Furthermore, using Quality by Design (QbD) methodology to
develop CE-based enantioselective techniques is becoming increasingly popular. The review presents
the current use of DoE methodologies in CE-based enantioresolution method development and
provides an overview of DoE applications in the optimization and validation of CE enantioselective
procedures in the last 25 years. Moreover, a critical perspective on how different DoE strategies can
aid in the optimization of enantioseparation procedures is presented.
Keywords: chiral separation; capillary electrophoresis; experimental design; screening; optimization;
quality by design
1. Introduction
Chirality is an important issue in modern pharmaceutical research, as strict conditions
are stipulated by the regulatory authorities for the introduction in therapy of new chiral
drugs. Food and Drug Administration (FDA) and European Medicines Agency (EMA)
require the pharmacokinetic and pharmacological characterization of both racemic mixture
and pure enantiomers of a drug candidate [1].
It is known that the desired therapeutic effect of a racemic substance is usually re-
stricted to one of the enantiomers, named eutomer, while the other enantiomer, named
distomer is less potent, or occasionally can present a different pharmacological effect;
in some cases, it can even be responsible for the adverse effects signaled after racemic
administration. In the last 25 years, the number of drugs introduced in therapy as pure
enantiomers has by far exceeded the number of drugs used as racemates, underlying the
importance of chirality in pharmaceutical research [1,2].
Molecules 2021, 26, 4681. https://doi.org/10.3390/molecules26154681 https://www.mdpi.com/journal/molecules
Molecules 2021, 26, 4681 2 of 40
Taking into consideration the aspects mentioned above, the development of new
analytical techniques for the enantioseparation of pharmaceuticals has become a necessity
and a challenge for the researchers. In particular, it is of great importance to develop reliable
chiral separation methods for the determination of enantiomers in different matrices,
such as bulk substances, pharmaceutical preparations, and biological samples. High
performance liquid chromatography (HPLC) is the most frequently used technique for the
analysis of pharmaceuticals, however capillary electrophoresis (CE) is being considered
today as an alternative and a complementary orthogonal approach [3].
CE offers a series of advantages in chiral separation of drugs at analytical scale, related
to the rapid method development, high separation efficiency, relatively short analysis
time, low consumption of analytes, reagents, and chiral selectors (CSs), high flexibility
in choosing and changing CSs. Moreover, by comparison with HPLC, the use of organic
solvents is much lower, consequently CE can be considered a “greener” option [4,5]. A
general advantage of CE is the rapid method development, because the experimental
conditions can be easily and rapidly changed from one experiment to another, without
the need of changing column as it happens for chromatographic methods. In CE, usually
a direct chiral separation method is used, simply consisting in the addition of CS to the
background electrolyte (BGE). A relatively large number of CSs can be applied in CE,
including crown ethers, macrocyclic antibiotics (aminoglycosides, glycopeptides), chiral
ionic liquids, chiral surfactants; however, by far the most efficient and frequently used are
the cyclodextrin (CD) derivatives (native and derivatized; neutral and ionized) [6,7].
CE is an official method of analysis in the 10th edition of the European Pharmacopoeia
(Eur.Ph 10), being subject to ICH-Q4B process; however, it is official only as a general
chapter, as there are no individual CE methods officinal for the chiral analysis of a certain
pharmaceutical [8].
Traditionally, the development of separation methods addressed at finding the best
conditions for analysis is performed by means of the univariate approach (“one factor at a
time”—OFAT) where an experimental factor is varied, while the others are kept constant.
Even if this approach can be efficient sometimes, it requires a relatively large number of
experiments, and does not allow for the evaluation of interactions between factors, which
may result in an inadequate conduction of method development and optimization, possibly
leading to a false optimum [9].
Design of Experiments (DoE) may be able to overcome these limitations by producing
higher quality of information and better results with a fewer number of experiments, thus
proving to be a powerful tool for development of CE-based enantioresolution methods. To
provide a better understanding of DoE applications, experimental designs can be divided
into two groups: screening and optimization designs. To emphasize even more the actuality
of the subject we can also mention that according to the recently introduced Quality by
Design (QbD) concepts, analytical methods should be developed and optimized using
DoE [10,11].
One of the first reviews dealing with DoE in CE, was published by Siouffi and Phan-
Tan-Luu in 2000 and presents optimization strategies using chemometric approaches in
chromatography and CE [12]. Sentellas and Saurina published two connected reviews
regarding chemometrics applications in CE; the first part describing optimization methods
while the second part dealing with data analysis [13,14]. A critical review on the develop-
ment in the use of chemometric DoE based optimization methods in CE was published by
Hanrahan et al. in 2008 [15].
Orlandini et al. published in 2014 an overview of applications of DoE for electro-
migration method optimization, including the critical discussion on the characteristics
of the chemometric methods (type of design, factors, responses) used to meet a range of
analytical issues, along with some practical advice and a list of the most typical challenges
encountered when setting up multivariate CE approaches [16].
To our knowledge, no comprehensive review dealing exclusively with the application
of DoE in the development of enantioseparation techniques by CE was published so far.
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The present paper provides an updated theoretical and practical overview for the
implementation of DoE in the development and optimization of CE methods used in the
enantioseparation of pharmaceuticals.
2. Experimental Designs Applied in CE Chiral Separations
2.1. Selection of Experimental Design
The main purpose of method set up in analytical chemistry is discovering the condi-
tions for an analytical procedure that produce the best possible analytical performance; in
this context, DoE plays a major role [17,18]. Method set up can be divided into two phases,
which represent two kinds of analytical issues: the screening and the optimization steps.
In the screening step, many factors are investigated in order to identify those exerting a
significant effect on the selected responses, while in the optimization step the factors are
further in-depth examined for identifying the best analytical conditions for optimizing the
responses [19]. After the optimization, DoE is also used in method validation for perform-
ing robustness testing and thus for evaluating the effect of small and deliberate changes in
the operating conditions on the method performances, and its use is also encouraged for
evaluating intermediate precision [20].
The selection of the proper experimental design to be applied should be carried
out by carefully taking into consideration several aspects, mainly related to the require-
ments/objectives of the study and to the phase of method development. Other fundamental
aspects to be considered for the choice of the right DoE are the known information, the type
of polynomial model that is estimated (linear or quadratic, with or without interactions),
the number of the factors, the operating cost, and time restrictions [18,21].
In general, in the screening phase and robustness testing, screening designs are applied,
while during the optimization phase response surface designs are used. A screening design
allows the evaluation of the effects of a relatively large number of factors from a relatively
small number of experiments, so that it is possible to establish the key factors influencing
the analytical performances of the method. A response surface design investigates the
most important factors, generally selected on the basis of the results of the screening phase,
in order to determine optimal experimental conditions by means of response surfaces or
contour plots [22,23].
2.2. Screening Designs
Many factors, both instrumental and related to the BGE, can influence the elec-
trophoretic enantioseparation and in general the analysis performance, it is thus necessary
to evaluate which of them have a significant effect on the responses. As a matter of fact, in
the first phase of CE method development the most influential factors, their optimal ranges
and their interactions are not yet known, and preliminary experiments are needed [15].
The screening study is the exploration of the factors which could have an influence on the
enantioseparation and is performed carrying out a minimum number of experiments on
a maximum number of factors. Due to the high number of factors studied, generally, a
linear model is hypothesized, and a highly fractionated design is needed. Mostly, screening
design involves variations of k factors at L = 2 levels, in a relatively small number N of
experiments (N ≥ k + 1) [24,25]. In addition to univariate preliminary experiments, the
experimental domain is usually chosen from literature information and by means of the
previous knowledge on the analytical issue under study.
The considered factors can be quantitative, i.e., changing on a continuous scale (con-
centration of CS, BGE concentration, BGE pH, temperature, voltage . . . ) or qualitative,
i.e., changing on a discrete scale (type of BGE, type of organic additive, type of CS . . . ).
After running the screening experiments, the evaluation of the significance of factors is
performed by statistical/and or graphical analysis of the coefficients in order to highlight
which factors have a significant influence on the responses. The statistical evaluation
generally includes the application of t-test or analysis of variance (ANOVA). Graphical in-
terpretation can be performed employing normal probability plots, half-normal probability
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plots, or Pareto charts. In the first two approaches the significant effects do not follow the
normal distribution and thus will deviate from the straight line drawn by the insignificant
factors while in the latter case, the standardized effects are represented as bars, and those
exceeding a line corresponding to the critical t-value are considered significant [23]. The
outcomes of the screening studies include the following: (i) the factors whose effect is not
significant can be fixed, thus reducing the number of variables to be considered in the
subsequent optimization phase; (ii) some factors which are significant can be fixed, if there
is no doubt on their optimal value, or they can be further studied in the optimization phase;
(iii) the experimental domain of the factors can be adjusted for approaching the analytical
target, moving towards the zone leading to promising results; (iv) the optimum level for
qualitative factors is established. Screening designs are also useful for validation studies,
typically in robustness testing; in this case, the experimental domain is much narrower with
respect to the typical ranges considered in screening studies prior to optimization [20,21].
2.2.1. Two-Level Full Factorial Design
Full factorial designs (FFD) are made by experiments with every combination of
factors’ levels, so that they consist in Lk combinations of L levels of k factors. In two-level
FFD, each factor is evaluated at two levels, called “high” and “low”, expressed as (+1) and
(−1) in coded variables [22]. When k is small, two-level FFD can be applied for screening
purposes, and N = 2k experiments have to be performed, allowing the estimation of main
and interaction effects [26]. Anyway, FFD quickly becomes infeasible as the number of
factors k increases, because this design is able to provide information on all interactions up
to k-th order and thus the number of required experiments rapidly grows due to the high
number of interaction terms of the model. This degree of knowledge is often unnecessary;
the third and higher-order effects can often be assumed to be negligible and usually bring
no useful information [24,27].
2.2.2. Two-Level Fractional Factorial Design
The two-level fractional factorial design (FrFD) permits to investigate a large number
of factors with a smaller number of experiments. It consists of a specific subset of experi-
ments obtained by fractioning a 2k FFD in a 2k−m design, where m is the size of the fraction
and 1/2m is the fraction of the original FFD [23]. The design must be balanced and chosen
so that the experiments map the experimental domain as well as possible, and orthogonal-
ity is preserved [24]. Different FrFD can be created for a large number of factors; the size
of the fraction influences the number of effects that can be estimated, and the number of
experiments needed [24,28]. A drawback of fractionating is that some information is lost
because only certain coefficients of the model are clearly calculated. As a matter of fact,
FrFD does not enable the estimation of all main and interaction effects separately, because
some of them are confounded, namely, they are estimated together [21,25,29].
Plackett-Burman Design
In Plackett-Burman design (PBD) L = 2 levels (−1, +1) are considered for each factor.
This matrix makes it possible to estimate linear models without interactions and thus
it finds useful application also in robustness testing. Anyway, in most cases, it can be
assumed that the influence of interactions of third-order or higher is negligible and thus
they can be excluded from the polynomial model [28]. The greatest advantage of PBD
consists in the possibility of screening a high number of factors with a low number of
experiments: a maximum of k = N − 1 factors can be examined in N experiments, where N
is a multiple of four [25]. As an example, this means that only 8 experiments are needed
for studying the effects of 7 factors, while only 12 experiments are required for studying
the effects of 11 factors. PBD is cyclical, the matrix is built from starting sequences with
coded factor levels for the first row (first experiment). The remaining rows of the matrix are
generated by cycling the end code to the beginning of the row and moving the rest of the
codes one place to the right. The sequence ends with all (−1) values, which corresponds to
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the last experiment (last row) in the matrix [24,25,27]. When k is higher than the number of
real factors to be examined, the remaining columns of the PBD are defined as dummy factor
columns, for which the change between the levels (−1) and (+1) has no physicochemical
meaning [24].
2.2.3. Asymmetric and Symmetric Screening Designs
Asymmetric screening designs (ASD) and symmetric screening designs (SSD) show
a great usefulness in gaining preliminary information on the influence of the variables
under study. The number of levels L for each factor is the same in symmetric designs and is
different in asymmetric designs; in any case L ≥ 2 (usually from 2 to 4). The possibility to
evaluate the effect of more levels of the same factor is an interesting characteristic, because
even if these designs cannot give a response surface as a result, they can furnish a clear
indication of the trend of the response obtained at the different levels of the factors. In
this way, it is possible to obtain valuable information for approaching the optimum values
for the factors and for giving indications on the choice of the experimental domain to be
studied in the subsequent optimization phase [26].
2.3. Optimization Designs
The optimization designs permit to obtain experimental data which can be fitted
in a quadratic polynomial model for generating a response surface, which describes the
behavior of the data set and makes previsions all throughout the experimental domain [17].
Response surface methodology (RSM) refers to multivariate techniques that can generate
response surfaces and provide solutions for selecting the optimum conditions, so that the
response is maximized, minimized, or even targeted to an optimal value [22,30]. In RSM
phase, first-order polynomial models with interactions, and consequently designs as FFD,
can be used only when the data do not present curvature, but usually, it is necessary to
use experimental designs capable to estimate the coefficients of second-order polynomial
models [17]. This is possible by employing designs where for each factor L≥ 3, because two
levels designs cannot give information about maxima or non-linear relationships. Another
important aspect is the efficiency E of the designs, determined as E = p/f, where p is the
number of coefficients in the polynomial model to be fitted and f is the number of factor
combinations in the experimental design [29]. As a matter of fact, when hypothesizing a
quadratic polynomial model, the number of coefficients to be estimated rapidly increases
with the increase of the number of factors to be evaluated. For this reason, for carrying
out RSM it is often desirable at a first stage to reduce the number of factors via screening
designs as described above. In this way, it is possible to select a small number of main
factors (three-five) to be studied in detail, for which both squared, and interaction terms
are of interest [31].
In RSM, qualitative factors cannot be examined; only quantitative and mixture-related
factors can be included in the study. Moreover, in order to be able in calculating models
for making previsions, it is necessary to perform some replicates of the center point
or duplicates/triplicates of each run. From these replicates, it is possible to obtain an
estimation of experimental variance, by which the validity of the model can be established.
After the statistical evaluation of the model has been performed, two-dimensional contour
plots or three-dimensional response surfaces can be drawn to visualize the trend of the
predicted response [22,23].
When selecting a response surface design, some of the desired features include:
(i) reasonable distribution of data points in the region of interest; (ii) allowing model
adequacy, including lack of fit, to be investigated; (iii) not requiring a large number of
runs; (iv) not requiring too many levels of the factors. Moreover, it is important for the
second-order model to provide good predictions throughout the region of interest; thus,
it has been suggested that the design should be rotatable, namely the variance of the
predicted values is uniform at all points that are at the same distance from the design
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center. These desired features can be sometimes conflicting, thus correct judgments by the
researcher must often be applied for selecting a suitable design [22].
Three-level full factorial design
Three-level FFD is seldom used, because the number of experiments is quite high
(N = 3k). It contains all possible combinations between the k factors and their L = 3 levels,
and the efficiency is rapidly lost with the increase of the number of the factors to be
studied [17,21].
Orthogonal array design
Orthogonal array design (OAD) is a kind of FrFD, based on a design matrix with
selected combinations of multiple factors at multiple levels. According to the orthogonal
array properties, between each pair of columns each combination of levels appears an equal
number of times. By this design it is possible to estimate the main effects and two-factor
interactions. OAD can be used both in the screening and in the optimization step as long
as the data do not present curvature [22].
2.3.1. Central Composite Design
Central composite designs (CCD) are made of two-level FFD points (2k experiments),
star points (2k experiments), and a number of replicates cp carried out at the center point,
so that the number of experiments is N = 2k + 2k + cp. The factors are studied at five
levels (−α, −1, 0, +1, +α). All the factors in the star points are set to 0, apart from one
factor which assumes the value ± α. The α value depends on the number of factors and is
usually included between 1 and
√
k. The design is made rotatable by the choice of α value:
α = (f )1/4 yielding a rotatable CCD, where f is the number of factorial design points [18,22].
CCD can be classified in circumscribed designs, where the star and the factorial points lie
equidistant from the center and |α| > 1, and in inscribed designs, where the star points lie
within the space of the factorial design and +α and −α are equal to the boundaries [21,24].
There is also a third kind of CCD, called Face Centered Central Composite Design (FCCD),
where α = 1, so that the star points lie on the faces of the hypercube, namely the faces of
the factorial design [24]. FCCD is often used because it requires only three levels for each
factor, and this can represent a practical advantage because in some cases it can be difficult
to change factor levels; anyway, it is not rotatable [22].
2.3.2. Box-Behnken Design
Box-Behnken design (BBD) is a modification of a three-level factorial design, where
one factor is kept at the central value in every experiment, plus at least one experiment
at the center. BBD can only be implemented for three or more factors; each factor is
studied at three levels, the experimental points are located on a hypersphere and are placed
equidistant from the central point [17,30]. The number of experiments is N = 2k (k − 1) + cp,
thus BBD designs are very efficient in terms of required runs, and they are either rotatable
or nearly rotatable [21,22]. The highest level and lowest level combinations for every
factor are not included in the design, thus this matrix is useful for avoiding experiments
in the extreme conditions, especially when these points represent combinations that are
prohibitively expensive or impossible to test for physical or technical constraints [22]. For
the same reason, its use should be suggested for the cases where the optimum is expected
to lie in the middle of the factor ranges [21].
2.3.3. Doehlert Design
In Doehlert designs (DD) the experimental points are distributed on a spherical shell.
The matrix is not rotatable, but it presents high efficiency, since the number of experiments
required is N = k2 + k + cp [22]. As for the distribution of the experimental points, for
two factors DD is a regular hexagon, while for three factors it is a geometrical solid called
centered dodecahedron [17]. Each factor is studied at a different number of levels: one at
three, one at five and all the other factors at seven levels. This can be useful to differentiate
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the study of the variables, since the factors which are considered more important, or which
have a larger domain, can be tested at more levels [21]. At the same time, this could
represent a drawback when a narrow experimental domain cannot be practically and easily
divided into seven levels. Another characteristic of DD is that the levels are uniformly
distributed, so there are equal distances between all neighboring experiments. Moreover,
the most important advantage is the potential for sequentiality: according to the obtained
results, it is possible to move the experimental matrix towards another experimental
domain for approaching the optimal zone, using previously tested points from the first
matrix [24].
2.3.4. D-Optimal Designs
Optimal designs are generated based on computer algorithms and can be used both for
screening and optimization. They are especially useful when the desired number of runs is
smaller than those required by a classical design or when the experimental regions are irregu-
lar [19,24,30]. The experimental domain is represented by a number of candidate experiments
and some mathematical criteria are used for choosing good sets of candidate points. Among
the different criteria available for the selection (D-criterion, G-efficiency criterion, A-criterion,
I-criterion, and others), the most common is D-optimality [19,30,32,33]. The experiments of the
D-optimal design (D-oD) are selected as the combination of experiments with the maximum
determinant for XTX, where XT is the transpose of the model matrix X. It can be demonstrated
that the precision of the coefficients estimate is directly correlated with the XTX matrix. This leads
to the minimization of the confidence interval for each coefficient, and thus to a higher precision
of the estimate [24–26]. An important characteristic of D-oD is that the researcher can specify
the maximum number of experiments that can be performed and can choose among different
matrices of different quality, made by a different number of experiments. The minimum number
of runs depends on the number of coefficients of the model, while the maximum number is
chosen by the researcher depending on the constraints imposed by the cost of experiments, the
time available, the desired quality of information. In this way a good compromise between the
quality of the matrix and the experimental effort can be achieved [19].
2.4. Model Evaluation and Validation
Once the polynomial model has been calculated, several tools are available for statisti-
cally evaluating its quality. The ANOVA allows to verify the model significance, namely
whether the factors can explain a significant amount of the variance in the response variable.
Moreover, if replicates have been performed or if an estimate of the pure error is available,
the validity of the model can also be checked [24]. ANOVA divides the total variation of
a selected response (SStot, total sum of squares) into a part due to the regression model
(SSregr, regression sum of squares) and a part due to the residuals (SSres, residual sum
of squares): SStot = SSregr + SSres. If replicates are made, the residual sum of squares
can be further partitioned into the sum of squares due to pure error (SSpe) and due to
lack of fit (SSlo f ): SSres = SSpe + SSlo f . By means of comparing the related mean squares
MS, obtained by dividing the SS values by the associated degrees of freedom, it is pos-
sible to evaluate the model significance and the model validity by means of a one-sided
F-test [19,24]. In order to test the significance of the regression, the main squares due to
regression MSregr is compared with the residual mean square MSres. If MSregr is signifi-
cantly larger, it means that the model is significant. Instead, the lack of fit test to check for
validity is performed by comparing MSlo f to MSpe. If MSlo f is significantly larger than
MSpe the model is inadequate, since the distance between measured and predicted values
of the response cannot be explained in terms of the pure experimental uncertainty; if MSlo f
and MSpe are comparable, the model is justified [24]. Sometimes the lack of fit might be
so small that it appears of no practical importance, but the F-test for lack of fit will show
that it is statistically significant. This often occurs when the model fits well the data, but
the experimental variance is very low. In this case, from the practical point of view, if
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the residuals are small enough to be considered acceptable, validity doesn’t need to be
verified [29].
Residual plots, where the residuals are plotted against the predicted values of the
response, can be also used for the evaluation of the model. The model is adequate when
no particular trend in the pattern of the residuals is observed and they are randomly
scattered, with a number of positive residuals approximately equal to the number of
negative residuals. This tool is particularly useful to verify if a linear model is inadequate
to describe the data; in this case, higher residuals (U-shaped) will be found at the center of
the plot, showing that there is a lack of fit with the linear model and that the data are better
represented by a curve [24].
Other parameters that are recommended to be used in evaluating the fit of a model
are the value of the coefficient of determination R2, adjusted coefficient of determination
R2adj, and predicted variation Q2. The coefficient of multiple determination is calculated
as R2 = SSregr/SStot = 1− SSres/SStot and is used to estimate the proportion of variation
explained by the regression, ranging from 0 to 1. However, its value increases with the
number of terms included in the model, either if a variable is significant or not. Therefore, it







which accounts for the number of model parameters p determined based on n num-
ber of experiments and has an optimum when additional terms do not provide further
value to the model [34]. The coefficient of predicted variation Q2 is the fraction of the
total variation of the response that can be predicted in the model and it is calculated as
Q2 = SStot − PRESS/SStot, where PRESS is the Predicted residual error sum of squares,
which is calculated by leave-one-out cross-validation. This represents a measure of how
well the model will predict the responses for new experimental conditions [19,22,24].
After a general evaluation of the proposed model, it may occur that the implemen-
tation of data transformation allows a better fit. Mathematical transformations apply a
mathematical function to all the measured responses, generating a new set of data, and
then a new model can be built to better explain the data behavior. Moreover, before mov-
ing on with a model, it is advisable to attempt model refinement. This can be done in a
sequential way, through the exclusion of the factors that are found to be not significant in
the coefficient plot, to obtain an improvement in the model predictivity Q2 [19,28].
Finally, if the model has been built for prediction purposes such as in RSM, it is
particularly important to extend the validation to independent data. Thus, new experiments
should be performed, and the measured observations will be compared with the predictions
from the model in order to verify their agreement [24].
2.5. Application of DoE in Analytical QbD
The application of DoE in the development of separation methods undoubtedly gives
important advantages, making it possible to obtain a high quality of information with a lim-
ited number of experiments. Anyway, it has to be highlighted that further improvements
in knowledge can be attained by applying QbD principles. The concept of QbD has been in-
troduced by the FDA as a quality paradigm to be used in the pharmaceutical field, with the
aim of explicitly designing quality into pharmaceutical products and processes. QbD was
approved by International Council for Harmonization (ICH), and dedicated ICH guidelines
were published shortly after [35–38]. This approach is based on process understanding
and control by quality risk management and has been transferred to the development
of analytical methods, with the name of Analytical Quality by Design (AQbD) [39–44].
Following the AQbD workflow, the method development can be divided into major several
steps: (i) definition of analytical target profile and method scouting; (ii) risk assessment
and definition of critical method parameters (CMPs) and critical method attributes (CMAs);
(iii) DoE for evaluating the effects of the CMPs on the CMAs; (iv) definition of the design
space (DS) or method operable design region (MODR); (v) method control. By means
of this systematic development it is possible not only to find the optimal conditions of
analysis, but also to obtain robust analytical methods. Within this framework, a key role is
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exerted by DoE, which gives the possibility of calculating mathematical models relating the
CMPs to the CMAs and locating the optimum zone by using multicriteria decision-making
tools. In general, at first screening designs are performed focusing on all the CMPs selected
by risk analysis, and then the optimization phase by RSM is carried out to gain in-depth
knowledge on the effect of selected CMPs.
2.6. Analytical Design Space and Method Operable Design Region
When a number of responses have to be optimized simultaneously by DoE, some
multicriteria decision-making tools are available, such as desirability studies or response
overlay. Individual response values can be combined in an objective function in order to
achieve an optimum value for all the responses [45], or the response surfaces can be overlaid
in order to graphically evidence the sweet spot, i.e., the zone where all the requirements are
fulfilled [18]. Anyway, it has been established that when developing an analytical method
by AQbD, for defining the optimum zone it is necessary to consider not only the predicted
values for CMAs, but also the probability that the CMAs requirements are fulfilled; in other
words, the definition of the DS is the main target [41,43].
In ICH Q8, the DS has been defined as “the multidimensional combination and
interaction of input variables (e.g., material attributes) and process parameters that have
been demonstrated to provide assurance of quality” [35]. For analytical methods, this has
been identified as a multidimensional space that includes any combination of the variables
that have been demonstrated to provide assurance of quality of the data produced by
the method [38,39]. In particular, the MODR for analytical methods has been defined as
the equivalent of the DS for manufacturing processes [43,44]. This is identified as the
zone where the requirements for the CMAs are fulfilled with a certain probability and
a selected risk of error, and it is computed by considering the uncertainty of the model
parameters [43]. For achieving this aim, different methods such as Bayesian modelling,
bootstrapping techniques or Monte-Carlo simulations can be used [43]. Among these,
Monte-Carlo simulations combined with interpretation of DoE response modelling make it
possible to estimate method uncertainty and thus to provide an adequate level of probability
that the CMAs specifications are met. Once the MODR has been calculated, the working
point to be used for routine analysis can be selected anywhere inside the MODR. From the
regulatory point of view, this means that a more flexible approach is achieved, because
any movement within the MODR is not considered a change, hence no revalidation of the
method is required [35,43].
3. Application of DoE in the Development of Chiral CE Methods
A relatively large number of articles dealing with applications of experimental design
approaches in the development of CE techniques (capillary zone electrophoresis—CZE,
micellar electrokinetic chromatography—MEKC, capillary electrochromatography—CEC)
for the analysis of chiral pharmaceuticals has been published. The following part of the
manuscript is a summary of the most important studies arranged chronologically in the
frame of each of the CE separation modality; the main aspects and trends in the application
of experimental design in chiral CE during the last 25 years are presented and discussed.
The articles were selected based on a literature screening survey on Google Scholar,
Pubmed, Scopus and Web of Science databases; the keywords used in the survey were:
chiral separation, enantioseparation, enantiomeric purity control, capillary electrophoresis,
experimental design, and quality by design.
3.1. Capillary Zone Electrophoresis (CZE)
CZE is the simplest capillary electrokinetic separation mode, based on the differences
in the charge-to-mass ratio of the analytes, hence all factors affecting the charge of the
analytes play an important role in selectivity adjustment. In particular, BGE pH, nature
and concentration, CS type and concentration, can influence the migration velocity of
the analytes and separation. Supplementing the BGE with CDs, is undoubtedly the most
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popular and successful approach to gain direct enantioresolution in CE. Under these
condition, transient diastereomeric host-guest type complexes with different inclusion
constants can be easily formed between the CD cavity and the two enantiomers, thus
differentiating their mobility. Noteworthy, in CE the separation can also be accomplished
in the case of enantiomers possessing the same binding constants with the CD, due to the
different mobility of the diastereomeric complexes [4]. Since inclusion complexation occurs
via Van der Waals, hydrophobic and electrostatic interactions as well as hydrogen bonding,
the enantioseparation is strongly affected not only by the nature of the CD but also by all
of the conditions influencing the inclusion complexation [4,6,7]. Thus, optimizing a chiral
separation involves the selection of several variables making the DoE the ideal approach
facing the challenge.
One of the first articles where DoE was applied for the development of a chiral
separation method by CE was published in 1994 by Rogan et al. for the enantioseparation
of clenbuterol, a sympathomimetic β-amino alcohol used in therapy as bronchodilator.
A PBD was applied to study simultaneously the effects of BGE concentration, BGE pH,
β-CD concentration, organic modifier (methanol) concentration, and injection time on
chiral resolution, migration time and peak efficiency. BGE concentration, BGE pH and
CD concentration were found to have significant effects on chiral resolution; migration
time was strongly influenced by BGE pH, while BGE concentration, BGE pH and injection
time affected peak efficiency. The results were compared with those obtained in a study
where an OFAT approach was used in the optimization process, published previously by
the same research group, in which good chiral separation was obtained using β-CD as
CS in a citrate/phosphate BGE at pH 4.0 [46]. Similar information but with much fewer
experiments was obtained in the case of PBD in comparison with OFAT. The CE method
was compared with a HPLC method using CDs as CSs, to identify a rational basis for the
transfer of knowledge on optimization between HPLC and CE. A generic optimization
strategy for the enantioseparation of new compounds, for which no previous investigations
have been carried out before was also proposed [47]. It was stated probably for the first
time that in chiral CE, scouting experiments have to be performed before an experimental
design-based optimization to acquire an indication of the chiral selectivity, peak shape, and
analysis time.
A CCD was applied by Small et al. for the development of a chiral separation method
by CE for amlodipine, an asymmetric dihydropyridine type calcium channel blocker. α-CD
was used as CS in an acidic phosphate BGE at pH 3.16. After an initial OFAT investigation
on the influence of several analytical parameters on chiral resolution, three factors (BGE
pH, α-CD concentration, temperature) were selected as significant and used in a CCD,
while the others (BGE concentration, voltage) were kept constant during the optimization
process; chiral resolution and Kaiser peak separation function were used as responses.
Optimum values predicted by the application of CCD were in excellent agreement with
those observed experimentally using the optimized parameters [48].
Boonkerd et al. investigated the enantiomeric purity of dexfenfluramine, a serotoniner-
gic anorectic drug by CE using dimethyl-β-CD (DM-β-CD) as CS. Two PBDs were applied
in the optimization process; the influence of BGE pH, DM-β-CD concentration, methanol
concentration, temperature and voltage on the chiral resolution, migration time and the
tailing factor of the last eluting peak was investigated. Interestingly, the first two responses
were combined in a composite quality response, to make a compromise between them. The
experimental conditions described previously by Bechet et al. were used as a starting point
of the method development and compared with the lower levels and higher levels in the
two complementary designs [49]. The reason for performing two parallel designs involv-
ing the same factors and responses may have the purpose to cover a larger experimental
domain. The optimized method was applied for the determination of levofenfluramine as
chiral impurity in dexfenfluramine samples, however, the resolution values below 1.5 may
not be enough for the quantitative determination of the second migrating distomer [50].
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Varesio et al. developed a CE chiral separation method for the enantioseparation of
five amphetamines (amphetamine, methamphetamine, 3,4-methylenedioxyamphetamine
(MDA), 3,4-methylenedioxymethamphetamine (MDMA), 3,4-methylenedioxyethyl
amphetamine (MDEA)). A CCD was used for method optimization, the influence of BGE
concentration, BGE pH, CD concentration, temperature and voltage on chiral resolution,
migration time and generated power was investigated. The results were compared with
the ones described previously in a OFAT method. The use of experimental design approach
allowed the separation to be developed using fewer experiments than a univariate devel-
opment would have needed. Also, response surfaces were drawn making it possible to
visualize the robustness of the separation [51].
Fanali et al. developed a chiral separation method by CE for the enantioseparation of
epinephrine. A neutral CD, heptakis-2,6-di-O-methyl-β-CD (HDM-β-CD), and an ionized
CD, carboxymethyl-β-CD (CM-β-CD), were used as CSs in a pH range between 2.5 and 7.0;
CM-β-CD gave the best results and was selected for the subsequent optimization. A FrFD
with five variables was used for screening purposes and a CCD with three selected variables
from the previous design was used for optimization in the method development. Chiral
resolution and migration times were selected as responses, a desirability function was used
to select a solution that assures minimization of migration times and maximization of chiral
resolution. The response surfaces obtained were used to establish the zones of optimum
robustness [52].
Guillaume and Peyrin proposed a chemometric method for the optimization of a chiral
separation method by CE of a mixture of 4 imidazole derivatives (bifonazole, econazole,
miconazole, sulconazole). The optimization process was composed of 9 or 18 preliminary
experiments, based on a FrFD, followed by further optimization by simplex methodology.
The selected factors were BGE pH, acetonitrile concentration in the BGE, β-CD concen-
tration and temperature, while the responses were chiral resolution, migration time and
number of theoretical plates. A phosphate BGE at pH 4.70, acetonitrile as BGE additive
and β-CD as CS were used in the optimized separation [53].
β-blockers are among the most interesting pharmaceuticals from stereochemistry
point of view, as all compounds are chiral and different activity between enantiomers
has been clearly established. Vargas et al. developed a generic chiral separation method
applicable in the case of 11 β-blockers (acebutolol, alprenolol, atenolol, bunitrolol, la-
betalol, metoprolol, oxprenolol, pindolol, propranolol, sotalol, toliprolol). An acidic phos-
phate/triethanolamine BGE and neutral DM-β-CD, hydroxypropyl-β-CD (HP-β-CD), and
ionized CM-β-CD, sulfobutylether-β-CD (SBE-β-CD) as CSs were used. Ionized CDs
proved to be efficient in the separation of basic β-blockers; CM-β-CD in eight cases while
the other three were enantioresolved using SBE-β-CD. Two different FrFDs were used,
one examining four factors at three levels (34-2) and the other examining three factors at
two levels (23-1). The selected factors were the type of CD, CD concentration, BGE pH
and percentage of methanol in the BGE; the selected responses were chiral resolution
and analysis time. The three-level FrFD was used to select the optimum CD, while the
two-level design was used to improve enantioresolution. The same strategy is suggested
to be efficient in the separation of other groups of pharmaceuticals [54]. The study proves
applicability and utility of DoE in the development of generic chiral separation methods
used in the enantioseparation of several pharmaceuticals with similar physicochemical
and structural characteristics.
The enantioseparation by CE of the β-blocker celiprolol, was reported by Daali et al.
using sulfated-β-CD (S-β-CD) as CS, in polyvinyl alcohol coated capillaries. An initial
evaluation of several CDs at two different pH levels was performed, and the best results
were obtained using acetate BGE at pH 4.0 and S-β-CD as CS. A CCD was applied for
optimization, considering as the selected factors the BGE concentration, BGE pH, S-β-CD
concentration, and temperature; the selected responses were chiral resolution, analysis
time and generated current. By studying the response surface of the quadratic model,
the optimal region which provides method robustness was established. The method was
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validated and used for the determination of celiprolol enantiomers in tablets and urine
samples [55].
de Boer et al. developed a CE method for the chiral separation of seven β2-sympath
icomimetic drugs (clenbuterol, fenoterol, isoprenaline, oxedrine, salbutamol, ritodrine,
terbutaline) using HP-β-CD as CSs in a polyethylene glycol (PEG) solution. Correlation
between the chemical structures of the analytes and CD were established; the compounds
having two hydroxylic groups substituted at the aromatic ring (isoprenaline, fenoterol,
terbutaline) were more easily separated, because their geometric structure better fits in
the β-CD cavity. A two factor CCD was used in the optimization process, using PEG and
HP-β-CD concentrations as variables and chiral resolution as response. The target for
chiral resolution was set to a minimum of 2.5, in order to use the developed method for
chiral impurity control (concentration as low as 0.1%) [56].
Zhu and Lin applied orthogonal and uniform designs for the optimization of chiral
separation of four model substances (disopyramide, ketamine, norfenefrine, synephrine)
using DM-β-CD as CS. The BGE pH, DM-β-CD concentration, voltage, and temperature
were set as variables in the design while chiral resolution was measured as response.
Orthogonal designs provide a quick and efficient method for identifying the significance
of individual parameters and establishing the optimum analytical conditions; however,
uniform designs are a more efficient tool when dealing with a high number of factors and
levels [57]. Combining uniform and orthogonal design for a complex separation system
could be a smart option in chiral separation method development, however, the presented
approach does not allow the study of second order and interaction effects, which can play
a crucial role in CE chiral separations.
Perrin et al. used a DoE strategy for the chiral separation of 14 amino acids by CE.
Three CDs were used as CSs: HP-β-CD, CM-β-CD and SBE-β-CD. The examined factors
were CD type, CD concentration, BGE pH and organic additive (methanol) concentration
in the BGE; chiral resolution was used as the response. Two types of FrFDs were applied
depending on the analytes: a 34-2 FrFD (4 factors at 3 levels) and a 23-1 FrFD (3 factors
at 2 levels). Among the 14 amino acids, 12 were enantiomerically baseline separated,
while 2 amino acids were not separated, and other separation systems were necessary. A
generic separation scheme was developed for the chiral separation of amino acids by DoE
approach; however, no generalization of the optimum analysis conditions was possible
within this group of compounds [58].
In another study, Gotti et al. used PBD for screening of factors and robustness testing of
a CE method for the chiral separation of salbutamol using a glycosaminoglycan, dermatan
sulphate, as CS. RSM using a DD was applied after the preliminary screening design; CS
concentration, BGE pH and voltage were selected as parameters and chiral resolution and
analysis time were chosen as the responses. Derringer desirability function was used to
simultaneously optimize the two responses. The method was applied for the determination
of salbutamol enantiomers in spiked human urine samples [59]. The study shows the
applicability of experimental design in CE chiral separation when other CSs than CDs are
used in the separation.
A chiral CE method using CDs as CS was developed by Mateus et al. for the enan-
tioseparation of atropine, a tropane structure alkaloid found in plants from Solanaceae
family. Prior to optimization, a complex CD screening was performed to establish the
optimum CS, and the best results were obtained with S-β-CD. A CCD was used for the
characterization of BGE concentration, BGE pH and S-β-CD concentration effects on the
chiral resolution, migration time and generated current. Under these optimized conditions,
baseline separation of littorine and atropine enantiomers was achieved in less than 5 min,
with high resolution values. The method was applied for the enantioseparation of atropine
in a pharmaceutical preparation (ophthalmic solution) and for the enantiomeric purity
evaluation of (−)-hyoscyamine in plant extracts, which can be useful in selecting the best
extraction procedure. Interestingly, the results showed that supercritical fluid extraction
induced less racemization than classical liquid-solid extraction procedures [60].
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Loukas et al. developed and validated a chiral separation method for peptides using
CE, CD as CSs and applying DoE for development. Ala-PheOMe was used as model
peptide while HP-β-CD as CS. A FCCD was applied; the selected factors were BGE concen-
tration, BGE pH, CD concentration and voltage while the responses were chiral resolution
and migration time. To optimize the two analytical responses (maximize resolution, min-
imize migration time) Derringer desirability functions were used [61]. In other types of
designs, the same strategy may be applied to find the levels of the predictor variables that
maximize overall response desirability: first, an effective prediction equation based on
the levels of the factors to match the observed product characteristics is used, and then
the levels of the factors that generate the most desirable predicted values simultaneously
are found.
In another study, Brunnkvist et al. developed a CE method for the chiral separation of
a tetrapeptide H–Tyr–(D)Ala–Phe–Phe–NH2. Two CSs, 18-crown-6-tetracarboxylic acid
and HDM-β-CD were tested observing that the crown ether gave better results; an acidic
phosphate BGE at pH 3.0 was used. An FFD was employed for robustness testing; the
factors BGE concentration, BGE pH, CS concentration and temperature were varied at two
levels, chiral resolution was used as response [62].
Saavedra and Barbas developed a chiral separation method by CE for lactic acid using
a DoE strategy. An initial complex CD screening was used to identify the optimum CS,
the best results were obtained when using HP-β-CD. Two three-level FFDs were used to
optimize analytical conditions; BGE concentration, BGE pH and HP-β-CD concentration
were used as variable factors, chiral resolution was used as analytical response. After the
first design, pH value was fixed at the value of 6.0 and in the second design the experimental
domains for both BGE concentration and HP-β-CD concentration were moved to higher
values. The method was validated for the determination of lactic acid in plasma allowing
the identification of both lactic acid isomers in body fluids such as urine, amniotic and
cerebrospinal fluids [63].
Harang et al. developed a CE chiral separation method for the enantioseparation of
propranolol using cellobiohydrolase (Cel7A) as CS. To identify significant experimental
variables, a series of preliminary experiments were carried out, followed by a FCCD, where
the influence of BGE pH, ionic strength, and organic additive (acetonitrile) concentration
on chiral resolution and separation selectivity, were evaluated. A high acetonitrile concen-
tration, high ionic strength and low pH resulted in improved peak symmetry and efficiency,
but at the expense of resolution and selectivity [64].
A DoE strategy was used for the CEC enantioseparation of a new synthesized aryl
propionic acid, namely 2-[(4′-benzoyloxy-2′-hydroxy)phenyl-propionic acid], with poten-
tial anti-inflammatory effect. Vancomycin was used as CS. Partial filling-counter current
method has been used to avoid the presence of the absorbing CS in the path length of the
detector and to increase sensitivity of the method. A CCD was used in the optimization,
the influence of CS concentration, BGE pH and temperature on chiral resolution and mi-
gration times was studied. Derringer desirability function has been used to simultaneously
optimize the two analytical responses [65].
A CE method was developed by Awadallah et al. for the CE enantioseparation of
ofloxacin, a fluoroquinolone antibacterial derivative, in highly diluted samples
(20–700 ng/mL for each enantiomer). Ofloxacin is used in therapy both in the form
of racemate, and as pure enantiomer, levofloxacin. Methyl-β-CD (M-β-CD) was used as CS
testing two injection methods: hydrodynamic and electrokinetic injection. A fluid-fluid ex-
traction from physiological solution was applied and electrokinetic injection was employed
to improve the sensitivity. A FCCD was used for method optimization, investigating the
influence of BGE concentration, BGE pH, M-β-CD concentration and temperature on chiral
resolution, migration time, peak area, and generated current. The limit of quantification
(LOQ) was found to be 11.4 ng/mL for S-ofloxacin and 10.8 ng/mL for R-ofloxacin [66].
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Marchesini et al. developed a chiral separation method for ketamine, a general
anesthetic, using CM-β-CD. A screening PBD, followed by a CCD optimization. The
method was applied for the determination of ketamine in pharmaceuticals [67].
Perrin et al. studied the effects of peak measurement and analysis parameters on
chiral CE, using as model compound an H1 antihistaminic derivative, dimethindene. The
influence of parameters related to UV detection (detection and reference wavelengths,
detection, and reference wavelength bandwidths), signal processing (data acquisition rate,
filter, and filter peak width), and peak detection (detection threshold, peak width) on
chiral resolution, peak area, and signal-to-noise (S/N) ratio, were studied at two different
concentrations levels (high and low S/N ratio) using a DoE strategy. A D-oD was first used
for screening the nine factors in ten experiments to identify the most significant param-
eters, followed by a FCCD for modelling different responses as a function of significant
parameters, namely data acquisition rate, filter, and filter peak width. The results revealed
that when designing a CE separation, signal-processing parameters should be carefully
chosen because setting these parameters at various levels will cause significant differences
in the measured separation, the S/N ratio, and the peak area [68]. Interestingly, peak
measurement/analysis parameters should be optimized as much as the method’s chemical
and physical parameters, since significant improvements in impurity detection and/or
identification, which is a crucial aspect in CE, can be achieved. The study also points out
that the robustness of a system can be severely harmed when the parameter settings are
transferred from one instrument to another.
The robustness of a generic CE chiral separation using highly sulfated CDs (HS-CDs),
a low pH phosphate BGE, and the short-end injection technique was tested by Perrin
et al. The robustness was evaluated for the enantiomeric separation of propranolol (basic
drug), praziquantel (neutral drug) and warfarin (acidic drug). The influence of eight
factors (BGE concentration, BGE pH, HS-CD concentration, temperature, voltage, sodium
hydroxide rinse volume, BGE rinse volume, injection time) which were considered to
significantly affect the separations, was studied by means of PBD [69]. The evaluation of
chiral separations was made in the context of developing a generic CE separation strategy
for different compounds. The study demonstrates the usefulness of DoE methodologies in
robustness testing and hereby the importance of recognizing the experimental parameters
which should be strictly controlled during the separation.
A screening strategy for the development of enantiomeric separation methods in CE
was proposed by Jimidar et al., based on a screening design as a function of pH to determine
the optimal separation conditions followed by a selection of the optimum CS by Taguchi
designs. In this approach several variables, such as the type and concentration of CDs, BGE
concentration, percentage of organic modifier in the BGE, were varied simultaneously; their
effect on the chiral resolution and migration time was evaluated. The strategy was applied
for the chiral separation of several chiral analytes under development [70]. In this study a
general strategy for the development of enantiomeric methods for basic, neutral, and acidic
compounds is proposed, which can be useful in managing resource time efficiently in
development laboratories. However, it can be noticed that capillary temperature which can
have a crucial effect on the chiral resolution, was not considered in the proposed strategy.
A comparative CE versus HPLC study was performed by Zhang et al. for the chiral
separation of 11 phenyl alcohol derivatives using S-β-CD as the CS in CE and a Chiralcel
OD-H column in HPLC. A DoE strategy was applied to determine the effect of BGE pH,
S-β-CD concentration and voltage on the chiral resolution, migration time and selectivity.
Moreover, the effect of the analyte structure on enantioseparation was evaluated: CD
concentration, the location of the aromatic group with respect to the asymmetric center
of the analytes and the substituent group connected to the chiral carbon, were found to
be factors influencing the complexation, selectivity, and resolution [71]. The comparative
study demonstrated that CE offers some advantages compared to HPLC for the separation
of the considered analytes, related to the shorter analysis time, and lower operational cost.
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Jimidar et al. applied a DoE approach for the CE chiral separation of an experimental
drug (R209130) with three asymmetric carbon atoms which led to eight stereoisomers. A
dual CD system consisting of α-CD and S-β-CD was selected as CS. The initial separation
conditions were optimized using a BBD; BGE concentration, α-CD concentration, S-β-CD
concentration, and voltage were selected as variables, chiral resolutions between enan-
tiomers and the migration time of the last peak as the responses. The method was validated
and proved to be suitable for chiral impurity control [72].
A multivariate optimization approach for CE chiral separation using human serum
albumin (HSA) as CS was published by Martinez-Gomez et al. Affinity electrokinetic
chromatography–partial filling technique was used, and four basic model compounds
were selected (alprenolol, oxprenolol, promethazine, propranolol). A BBD was applied
in the optimization process; BGE pH, HSA concentration and HSA solution plug length
were selected as variables. Pareto charts and partial least squares analysis were used
to examine the effects of experimental variables on chiral resolution. In addition, the
effect of the physico-chemical properties of model analytes, acid–base ionization constants,
octanol-water partition coefficients and analyte–HSA protein binding percent on the chi-
ral resolution was established. The results reveal that analyte–HSA interaction strength
and the consequent enantiomer resolution, is largely determined by analyte hydrophobic-
ity; when the hydrophobicity decreases, the range of experimental conditions that yield
enantioresolution, narrows [73].
An interesting study was published by Elek et al. in which two different dual CS
systems containing a CD derivative (M-β-CD, DM-β-CD) and a new diaza-crown-ether
derivative (N-[2-(1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)propanoyl]glycine) were
studied in the chiral separation of tryptophan- and tyrosine-methylester enantiomers. A
CCD was used for optimization; CD concentration, crown-ether concentration and BGE
concentration were set as variable factors whereas chiral resolution and migration time
were selected as responses. The dual CS systems proved to enable better chiral separation
of amino acid derivatives [74].
Zhang et al. developed a CE method for the chiral separation of tamsulosin, an α1
receptor antagonist, used in the treatment of benign prostate hyperplasia in the form of
pure enantiomer, S-tamsulosin. S-β-CD was chosen as CS. Response surface method-
ologies such as BBD, FCCD, and central composite circumscribed (CCC) design, were
comparatively used for the optimization. CD concentration, voltage and temperature were
chosen as variable factors, and their influence on chiral resolution and migration time was
observed. The design points for all three approaches are guaranteed to fall inside a safe
operating zone, with similar optimization and prediction results. Baseline separation of
the enantiomers was obtained quickly during 3 min, with a resolution higher than 1.5 [75].
The study confirms the principle that the applied three response surface designs can serve
as alternatives to each other.
A CE chiral separation method was developed by Danel et al. for the enantioseparation
of 9-hydroxyrisperidone, the main active metabolite of risperidone, an antipsychotic drug.
A dual CD system was employed, composed of neutral HP-β-CD and anionic S-α-CD at
an acidic pH of 2.5. A CCD was used for method optimization, selecting experimental
factors as: HP-β-CD concentration, S-α-CD concentration and BGE concentration; the
analytical responses were chiral resolution, migration time, selectivity, and plates number.
The influence of temperature and voltage was studied using a OFAT strategy, however,
both parameters had a great impact on the migration time and the chiral resolution as well.
Probably the inclusion of these two factors in the multivariate optimization could be useful
for detecting possible interactions with the other factors. The method was applied for the
simultaneous determination of risperidone and 9-hydroxyrisperidone enantiomers, and
it could be used for the determination of analytes in biological samples, to characterize
risperidone metabolism [76].
An experimental design strategy was used by Sungthong et al. for the development
of a CE stereoselective method for the simultaneous determination of S-citalopram chiral
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impurities, including its distomer, R-citalopram, and a synthetic intermediate, S-citadiol.
Citalopram is a selective serotonin reuptake inhibitor (SSRI) antidepressant, used in therapy
first in the form of racemate and then as pure enantiomer, S-citalopram, being a successful
example of “chiral switch” among pharmaceuticals. After an initial CD screening, a dual CD
system composed of native β-CD and anionic S-β-CD was chosen as the optimum CS for the
separation. A FCCD was used in the study; the influence of four factors, BGE concentration,
S-β-CD concentration, voltage, temperature over the chiral resolutions between the four
enantiomers, migration time of the last migrating enantiomer and generated current was
evaluated. BGE pH was set at 2.5 as the analytes are basic, and the concentration of the
second CD, β-CD, was kept constant during optimization, based on preliminary results.
The method was validated and allowed the detection of the impurities at a 0.05% level
relative to S-citalopram at a concentration of 5 mg/mL. The assay was used to check the
purity of S-citalopram in both bulk samples and tablets [77].
A BBD was used by Borges et al. for the development of a CE chiral separation method
for the simultaneous enantioresolution of propranolol and its main active metabolite,
4-hydroxypropranolol. CM-β-CD was used as CS in a triethylamine/phosphoric acid BGE
at a basic pH. The influence of four factors, namely BGE concentration, BGE pH, CM-β-CD
concentration, and voltage on chiral resolution and migration time, was studied. The
method has the potential to be used in quality control of pharmaceutical formulations, but
also in pharmacokinetic and metabolic studies [78].
Gomis et al. developed a CE chiral separation method for the enantioseparation
of zopiclone, a sedative-hypnotic substance and one of its synthesis precursors. For
optimization, a FFD was used; four factors were selected, BGE concentration, BGE pH,
β-CD concentration and voltage, and their influence on chiral resolution and migration
time was studied. The results of the method, compared with a previously published HPLC
method, proved CE to be superior in terms of number of theoretical plates, migration time
and cost-effectiveness. The method can be used to evaluate the presence of chiral synthesis
intermediates and the enantiomeric purity of zopiclone [79].
A CE method for the separation and determination of clopidogrel impurities was
developed by Fayed et al. Clopidogrel is an anti-platelet dihydrothienopyridine derivative
prodrug, used in therapy in the form of a pure enantiomer, S-clopidogrel; in this study the
presence of the distomer, R-clopidogrel and two other chemically related substances was
investigated. A reduced CCD was used to study the effects of BGE concentration, BGE pH,
S-β-CD concentration and voltage on the chiral resolution and migration time. The method
was validated and used for S-clopidogrel purity control in bulk commercial samples [80].
Liu et al. developed a CE method for enantiomeric purity control of RS86017, a poten-
tial antiarrhythmic drug with two chiral centers using SBE-β-CD as CS. BGE concentration
and pH, SBE-β-CD concentration, organic modifier concentration, temperature, and volt-
age were systematically optimized by OAD and CD concentration was further optimized
using a OFAT strategy. The optimized method was validated and was capable of separat-
ing the R,S-enantiomer of RS86017 from its potential chiral impurities, S,R-enantiomer,
R,R-diastereomer and S,S-diastereomer, in a relatively short analysis time of 10 min. The
values of limit of detection (LOD) and LOQ were 0.8 µg/mL and 2.5 µg/mL, respec-
tively for all enantiomers. The procedure can be useful for the quality control of the pure
enantiomeric drug product [81].
Chiral separation by CE of dapoxetine, a serotonin transporter inhibitor for the treat-
ment of premature ejaculation has been achieved by Neumajer et al. using randomly
methylated γ-CD (M-γ-CD) as CS. Dapoxetine is used in therapy in the form of pure enan-
tiomer, S-dapoxetine. To establish the optimum CS a wide range of CDs has been tested
at various concentration levels, also the apparent binding constants were calculated. An
OAD was used to optimize experimental parameters; the influence of BGE concentration,
BGE pH, M-γ-CD concentration, organic additive (methanol) concentration, temperature,
voltage on the chiral resolution was investigated. The method was validated, and a PBD
was applied for robustness testing [82].
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A few years later, Harnisch and Scriba published a CE method for the determination
of S-dapoxetine chiral purity regarding its distomer, R-dapoxetine and another chemical-
related impurity. An initial CD screening at two concentration levels and three pH levels
was applied in the preliminary analysis. A dual CD system containing DM-β-CD and
sulfated-γ-CD (S-γ-CD) was used in the separation. For the optimization of the analytical
conditions, a FrFD was used for screening followed by a CCD with Monte Carlo simulation
to define the design space. The robustness of the method was verified by a PBD. The
method was validated and applied for analysis of dapoxetine in tablets. The method was
able to determine the impurities at a level as low as 0.05%. The results of the CE assay
for enantiomeric purity of dapoxetine were comparable to those of an enantioselective
HPLC approach [83]. The assay is an example of how CE may be used to evaluate related
compounds and enantiomeric impurities in a single run.
Zhang and Du applied two new amino acid ionic liquids as CS in the enantiosepa-
ration of pharmaceuticals and evaluated their potential synergistic effect with glycogen.
Three chiral model molecules were used in the study (citalopram, duloxetine, nefopam).
When compared to the results achieved involving only glycogen as the CS, the chiral
ionic liquids/glycogen synergistic systems significantly enhanced enantiomer separation.
Several major enantioseparation factors, such as the concentration of amino acid ionic
liquids, glycogen concentration, and BGE pH, were extensively studied in a univariate way;
however, considering the aim of this study a multivariate approach could be particularly
useful to detect interactions between ionic liquids and glycogen. The influences of three
other parameters, BGE concentration, voltage, and temperature, were simultaneously
assessed by a CCD to further improve the overall synergistic system [84].
Asensi-Bernardi et al. proposed a modelling strategy to assess the chiral separation
ability of highly sulphated-β-CD (HS-β-CD) as CS. In this study a discriminant partial
least squares (PLS)-based quantitative structure-property relationship (QSPR) method
was simplified, being translated into an explicit equation that may predict the enantiores-
olution of new analytes using four structural parameters found in open databases: the
logarithm of the octanol-water partition coefficient calculated at pH 7.4, polar surface
area, number of hydrogen bond donors, and acceptors. In the situations when the model
predicted enantioresolution, a BBD was proposed for fast PLS-based optimization using
as experimental design factors: BGE pH, CD concentration and temperature [85]. This
study is a good example of how different theoretical and computational approaches can
work in a complementary way to reduce the number and the cost of experiments during
method development.
A chiral CE method using a dual CD system composed of a cationic and neutral
CDs was developed for the enantiomeric separation of a compound presenting a diaryl
sulfonamide group by Rogez-Florent et al. A dynamic cationic coating of the capillary
was used to prevent adsorption of the amino-β-CD to the capillary wall. The method
was optimized using a CCC design with three experimental factors: amino-β-CD and
β-CD concentrations and methanol percentage in the BGE. The design results showed a
significant interaction effect of the two CDs on chiral resolution [86].
Wahl and Holzgrabe developed a CE method for the evaluation of enantiomeric pu-
rity of magnesium-L-aspartate dihydrate. A CE method using HP-β-CD coupled to laser
induced fluorescence (LIF) detection and a HPLC-fluorescence method using chiral deriva-
tization by o-phthaldialdehyde and N-acetyl-L-cysteine were developed and validated. A
three level FFD was used to investigate the influence of the effects of BGE concentration,
BGE pH and CD concentration, on the resolution between L- and D-aspartic acid. The
method was used for the determination of D-aspartic acid content in bulk samples and
dietary supplements [87].
QbD concepts were applied for the analysis of levosulpiride, an atypical antipsychotic
in a study by Orlandini et al. A dual CD system composed of S-β-CD and M-β-CD was
used as CS in the separation. By conducting a screening design comprising both qualitative
(neutral CD type) and quantitative (BGE concentration, BGE pH, neutral and ionized CD
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concentrations, voltage) factors, as well as a response surface investigation, this separation
system was thoroughly explored using multivariate approaches. The qualitative factor
was studied at two levels, while the quantitative factors were all assessed at three levels.
RSM was carried out using a DD to highlight significant interactions between critical
process parameters. Design space was defined by applying Monte Carlo simulations. A
PBD was applied for robustness testing. The method was validated and applied for the
determination of enantiomeric purity of levosulpiride in pharmaceutical dosage forms [88].
To the best of our knowledge, this was the first time a QbD approach has been used to
systematically determine enantiomeric purity in a pure enantiomer medication. The use of
a QbD approach in the development of a CE methods allowed for a more reasonable and
systematic approach to optimization difficulties, providing for a better understanding of
the chiral separation.
The enantiomers of asenapine, a novel antipsychotic agent with a dibenzooxepino
pyrrole structure used in schizophrenia, were separated by CE by Szabó et al. Asenapine
has two chiral centers in its structure, however, it is used in therapy in the form of a racemate
composed of R,R- and S,S-enantiomers. The stability of the inclusion complexes and the
enantiodiscriminating ability were investigated with different CDs, showing β-CD as the
most promising. An OAD was used for method optimization, varying in a multivariate
manner the BGE concentration, BGE pH, β-CD concentration, organic modifier (methanol)
concentration in the BGE, temperature and voltage; the response being the chiral resolution.
Molecular modelling, NMR spectroscopy, and ESI–MS were used to identify the complex’s
stoichiometry and shape. The analyte-CD complex was found to have 1:1 stoichiometry,
and either of the two aromatic rings may be fitted in the CD cavity [89].
The same research group published a CE chiral separation method for the enantiosep-
aration of pomalidomide, a thalidomide derivative used as an immunomodulatory drug.
As the drug is neutral, ionizable CDs were used in the screening to establish the optimum
CS; CM-β-CD was found to be the most efficient. An OAD was used to optimize BGE
concentration, BGE pH, temperature, and voltage; chiral resolution was selected as ana-
lytical response. The method was validated and allowed the baseline separation of the
enantiomers with high resolution values [90].
In a study by Szabó et al., different CDs and polysaccharides were used as CSs,
in two complementary methods (CE, HPLC) to investigate enantiomeric resolution of
lenalidomide, an immunomodulatory agent. HPLC separation was achieved using a
polysaccharide type chiral stationary phase (CSP) in polar organic (PO) mode. In the case of
CE separation, after a preliminary screening of several anionic chargeable CDs, SBE-β-CD
was chosen as optimum CS. An initial OFAT strategy was applied for method optimization,
followed by a FCCD for fine-tuning the separation. The method was validated and allowed
the determination of 0.1% R-lenalidomide [91].
Chiral separation of vildagliptin by CE, an oral antidiabetic from the DPP-4 inhibitor
class, was reported by Kazsoki et al. Vildagliptin is used in therapy in the form of pure
enantiomer, S-vildagliptin, R-vildagliptin being considered as its chiral impurity. After
a complex screening of 13 CDs, SBE-β-CD was chosen as optimum CS. Optimization
was performed using an OAD; the influence of BGE concentration, BGE pH, SBE-α-
CD concentration, temperature, voltage, and injection parameters on chiral resolution
was verified. After the multivariate optimization, it was observed that the second peak
(S-vildagliptin) migrated too close to the electroosmotic flow (EOF), which would influence
chiral purity control. To fine-tune the optimization, in a second step the OFAT approach
was applied. However, as an assumption, if the Authors had used first the OFAT method to
identify the conditions in which the vildagliptin enantiomers were separated and migrated
far from EOF, and after that the OAD, this flaw may have been avoided. Another possibility
could also be to include the time distance of the peak, from EOF, as the second response to
be directly evaluated by OAD. The method was validated; LOD and LOQ values were 2.5
and 7.5 µg/mL, for R- and S-vildagliptin, respectively. The robustness of the method was
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verified using a PBD. The method was applied to control the chiral purity of S-vildagliptin
in pharmaceutical formulations [92].
A CE method for the determination of chiral purity of ambrisentan was published
by Krait et al. Ambrisentan is an orphan drug used in the form of pure enantiomer,
S-ambrisentan, as a selective endothelin receptor antagonist for the treatment of pulmonary
arterial hypertension. γ-CD was used as CS in the enantioseparation. The approach was
developed using a FrFD to identify the significant factors followed by a FCCD response
surface approach and Monte Carlo simulations to generate the DS. PBD was used for
robustness testing. The method was validated and allowed the determination of 0.1%
concentration of enantiomeric impurity R-ambrisentan [93].
A CE method for the determination of three chiral impurities of sitafloxacin, a
chemotherapeutic fluoroquinolone, was developed by Meng and Kang. Sitafloxacin has
three chiral centers, which generates the presence of eight stereoisomers; however, due
to stereoselective synthesis at least two pairs of enantiomers (four stereoisomers) may be
present in the bulk substance. A dual CS system containing γ-CD and
Cu2+-D-phenylalanine was used; the combination of the two CSs enhanced stereoselectivity
through the combination of separation mechanisms: inclusion-complexation (CD) and
ligand exchange (Cu2+-D-Phe). A FrFD was used in the screening, involving seven factors,
and a FCCD was used in the optimization, studying the influence of BGE pH, γ-CD, Cu2+,
D-Phe concentrations on chiral resolution and migration time. Concentration of impurities
as low as 0.1% with respect to sitafloxacin eutomer can be detected using the validated
method [94].
CE chiral separation of fluoxetine, a SSRI antidepressant, was reported by Cârcu-
Dobrin et al. Fluoxetine is used in therapy as a racemate, however, its metabolism is
stereoselective, making chiral methods useful in pharmacokinetics studies. To establish the
optimum CS, a vast variety of native and derivatized, neutral and ionized CD derivatives
were examined at three pH levels; heptakis (2,3,6-tri-O-methyl)-β-CD (HTM-β-CD) at
pH 5.0 was chosen for enantiomeric differentiation. An OAD was applied in the optimiza-
tion process: the influence of BGE concentration, BGE pH, CD concentration, temperature,
voltage, and injection parameters on enantioresolution, was tested. The method was
validated and applied for the enantioseparation of fluoxetine in pharmaceuticals [95].
A CE method for the determination of chiral purity of pregabalin upon derivatization
with dansyl chloride was developed by Harnisch et al. Pregabalin, a γ-aminobutyric acid
analogue, is used in the form of pure enantiomer, S-pregabalin, as anticonvulsant and
anxiolytic. HTM-β-CD was used as CS. Initially a FrFD design was applied, however peak
tailing was detected at low BGE concentrations; when BGE concentration was increased, the
peak tailing impact was minimized. As a result, the experimental zone had to be changed
to incorporate larger BGE concentrations, resulting in an asymmetrical experimental zone.
Thus, a D-oD was used for screening to identify significant parameters, while a FCCD and
Monte Carlo simulations were employed for further optimization and to define the DS
of the method, respectively. The robustness of the method was tested using a PBD. The
method was validated and allowed the detection of R-pregabalin at the 0.015% level with a
LOQ at the 0.05% level in a sample containing 1.59 mg/mL pregabalin [96].
A CE method has been developed according to QbD principles by Krait and Scriba
for the chiral purity determination of dexmedetomidine. Dexmedetomidine is a selective
α2-adrenergic agonist used as general anesthetic in the form of a pure enantiomer. The ana-
lytical target profile was set to determine the distomer levomedetomidine, with appropriate
precision and accuracy at 0.1% level. After an initial CD screening, S-β-CD was selected as
CS. A FrFD was utilized to identify the significant process parameters, followed by a FCCD
as optimization design and Monte Carlo simulation to define the method’s design space.
The robustness of the method was assessed using a PBD. The method was validated and
applied for the determination of dexmedetomidine in tablets [97]. For the identification of
the critical process parameters (CPPs), which are the experimental factors that impact the
method’s critical quality attributes (CQAs), this methodology uses risk-assessment tools.
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This approach leads to a quantitative knowledge of the probability for the requirements for
CQAs to be fulfilled.
From the article mentioned above we selected Figure 1 which shows the plots obtained
with Monte Carlo simulation for concentrations of S-β-CD of 30, 40 and 50 mg/mL; the
design space (green zone) defines combinations of parameters where the risk of failure is
below 1%, to meet the three selected criteria, separation factor-value above 1.05, generated
current below 100 µA, and migration time of dexmedetomidine below 10 min. It can be
observed that the larger space is found in the case of 40 mg/mL S-β-CD concentration [97].
Figure 1. Probability plot of the design space obtained by Monte Carlo simulations in the case of
dexmedetomidine. Reprinted from Krait and Scriba [97] with permission from Wiley.
The same researchers developed a chiral CE implementing QbD principles for the
determination of dextromethorphan chiral purity using a dual selector system, composed
of methyl-α-CD (M-α-CD) and S-β-CD. Dextromethorphan is a centrally acting antitussive
medication, but its enantiomer, levomethorphan, is an illicit opioid analgesic. A FrFD was
used to assess the significant analytical parameters, followed by a FCCD and Monte Carlo
simulations to define the method’s DS. After selecting the optimum working conditions, a
PBD was used to assess the method’s robustness before it was validated. To understand
the migration behavior of the analytes, the apparent binding constants between the enan-
tiomers and the CDs, as well as complex mobilities, were calculated. The method was
used to determine the stereochemical impurity levomethorphan in dextromethorphan bulk
substance and pharmaceutical formulations at 0.1% level [98].
Pasquini et al. applied QbD principles for the determination of chiral purity of R-
cinacalcet, a calcimimetic drug, and two other related chiral impurities. A preliminary CD
screening was applied to establish the optimum CS, and HP-γ-CD was selected as the best
solution. A BBD was applied for method optimization; BGE pH, HP-γ-CD concentration,
methanol concentration and voltage were selected as variables; their effect on chiral resolu-
tion and migration time was investigated. The mathematical model developed by using
BBD allowed for a more in-depth knowledge of the response behavior; the researchers
focused on the conditions that would allow to achieve higher resolution of enantiomers
and the synthesis impurities and lower migration times. Using Monte-Carlo simulations,
the MODR was found as the multidimensional zone where both critical method attributes
satisfied the requirements with a desirable probability. The QbD methodology aided in
determining the experimental zone in which the likelihood of failing to meet the previously
stated criteria was lower than 10%. A PBD was used to verify robustness; the method was
validated and applied for cinacalcet determination in pharmaceuticals [99].
Vargas-Martínez and Ramírez-Galicia developed a CE method for the enantiosepara-
tion of four chiral benzodiazepines (lorazepam, lormetazepam, oxazepam, temazepam).
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Three CDs were tested: heptakis-6-sulfato-β-CD (HES-β-CD), heptakis(2,3-di-O-acetyl-6-O-
sulfo)-β-cyclodextrin (HDAS-β-CD), heptakis(2,3-di-O-methyl-6-O-sulfo)-β-cyclodextrin
(HDMS-β-CD); the best results were obtained when using HES-β-CD. A 34-2 FrFD was
applied in the optimization; CD type, CD concentration, BGE pH, percentage of methanol
in the BGE were selected as factors. The apparent equilibrium constants for the formation
of the benzodiazepine-CD complexes were calculated, and a theoretical investigation of the
interaction between the benzodiazepine and the HES-β-CD complex was proposed using
semiempirical calculations [100].
Wahl and Holzgrabe proposed the application of ionic liquids combining tetrabutylam-
monium cations with chiral amino acid-based anions as BGE additives for the enantiosepa-
ration of phenethylamine (ephedrine, methylephedrine, pseudoephedrine) enantiomers,
while β-CD was used as a CS. BGE pH, and ionic liquids concentration were optimized
using a three level FFD [101].
An interesting study using DoE, in which one of the major drawbacks of CE, transfer
of CE methods, is discussed was published by De Cock et al. A further weakness of CE is
the lower sensitivity when compared to HPLC; improving and maintaining sensitivity is
the reason why inter-instrumental differences across detector settings should be prioritized.
The chiral separation of two β-blockers (betaxolol, propranolol) was considered as a
case study. The influence of several detector parameters, including data acquisition rate,
bandwidth, and filter, on several responses (peak area, height, and width, signal-to-noise
ratio, peak asymmetry, migration time, efficiency, resolution), was evaluated by robustness
testing performed on two CE instruments [102]. This research is part of a wider initiative
that aims to provide standards for transferring CE procedures between different devices
or laboratories.
A generic CE method was proposed by Abdel-Megied et al. for the chiral enantiosepa-
ration of different basic and acidic drugs; anti-Alzheimer (donepezil, rivastigmine) and
antimycotic (fluconazole, itraconazole, ketoconazole, sertaconazole) drugs were considered
as model solutes. Several neutral and charged CDs were tested as CSs. An initial OFAT
study was approached for screening purposes followed by a FFD using two significant
factors (BGE pH and CD concentration) at three levels for optimization. The best results
were obtained when using SBE-β-CD at low pH values and high CD concentration [103].
However, the regression results indicated that the linear model shows a significant lack of
fit for all CDs, implying that higher orders of the factors are most likely to be included in
the equation with possible interactions.
Two chiral separation CE methods for the enantioseparation of proton pump inhibitors
(lansoprazole and rabeprazole, respectively) were developed by Papp et al. A high number
of neutral and ionized CDs were screened at two pH levels to identify the optimum CS, and
SBE-β-CD was selected as the best option. Furthermore, various dual CD systems were
tested, and possible separation mechanisms were studied; a dual CD system containing SBE-
β-CD and γ-CD was finally considered to be the most adequate for the enantioseparation.
An initial FrFD was used for identifying significant experimental factors followed by CCD
to establish optimum analytical conditions. The method was validated and used for the
determination of 0.15% distomer in dexlansoprazole and dexrabeprazole samples [104].
CE chiral separation of tramadol, a centrally acting analgesic drug, was reported
by Sarkany et al. Tramadol has two chiral centers which generates four stereoisomers,
however, it is used in therapy as a racemic mixture of the trans enantiomers, R,R- and
S,S-tramadol. Charged and uncharged CDs were screened at four pH levels to establish the
optimum CS; CM-β-CD in a basic BGE was selected as the best solution. After a preliminary
OFAT approach a FCCD was used to establish the optimum electrophoretic conditions.
The analytical performance of the method was verified, and the method was applied for
the determination of enantiomer ratio of tramadol in pharmaceutical preparations [105].
From the article mentioned above we selected Figure 2 which presents 3-D response
surface plots representing the influence of three significant factors (pH, CD concentration,
temperature) on the two selected analytical responses (chiral resolution, migration time).
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Niedermeier and Scriba published also a QbD guided method development for
the determination of dextrodropropizine and 1-phenylpiperazine as impurities in lev-
odropropizine samples. Levodropropizine is a non-opioid peripherally acting drug used
as antitussive, in the form of pure enantiomer. Initially, a CD screening at three pH levels
testing a large number of neutral and anionic CD derivatives was performed and even-
tually S-β-CD was selected as optimum CS. A FFD was used to study the effect of CD
concentration, temperature, voltage, and 2-propanol concentration on the selected CQAs of
the method (separation factors, migration time, generated current). The following method
optimization consisted of a two-factor FCCD for further studying CD concentration and
temperature, then the design space was determined by Monte Carlo simulations. An addi-
tional robustness testing was carried out using a PBD before the method was validated and
applied for the analysis of levodropropizine bulk samples and pharmaceutical drops [106].
This study is a good example of the simultaneous determination of chiral and achiral
impurities of an enantiopure drug.
Another CE chiral separation method for the enantioseparation of amlodipine was
developed by Cârcu-Dobrin et al. CM-β-CD in a basic BGE was selected as CS, based on
an initial CD screening at four pH levels. An OAD was used for method optimization,
examining six experimental factors: BGE concentration and pH, CM-β-CD concentra-
tion, temperature, voltage, and injection parameters. The analytical performance of the
method was verified, and the method was applied for the determination of amlodipine in
pharmaceutical preparations [107].
The enantioseparation of citalopram was published by Budău et al., based on an initial
CD screening at four pH levels; CM-β-CD was selected as optimum CS. For method opti-
mization, an experimental design approach was utilized: a FrFD was applied for screening
to identify significant experimental parameters, followed by a FCCD for optimization. To
help in the understanding of the chiral separation mechanism, computational modelling
was employed allowing to gain information on the interaction energy and shape of the
analyte-CD complexes. The method was applied for the determination of enantiomers in
racemic formulations and optical purity control of S-citalopram [108].
The same research group worked on a CE method for the enantioseparation of ven-
lafaxine published by Milan et al. Venlafaxine is an antidepressant from serotonin and
norepinephrine reuptake inhibitor (SNRI) class, used in therapy as a racemate, however
differences between pharmacological profiles of the enantiomers are known. CD screening
at four pH levels led to the conclusion that CM-β-CD in an acidic BGE is the optimum
CS. An initial OFAT screening technique was utilized to determine the impact of analyti-
cal parameters on the enantioseparation, followed by an optimization procedure using a
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FCCD. To describe host-guest chiral recognition, computer modelling of venlafaxine-CD
complexes was applied. The method was validated and used for the determination of
venlafaxine enantiomers in pharmaceutical formulations [109].
3.2. Capillary Electrophoresis—Mass Spectrometry (CE-MS)
One of the few chiral CE-MS methods developed by DoE was published by Rudaz
et al. for the enantioseparation of methadone, a synthetic opioid agonist. A capillary
electrophoresis coupled with electrospray ionization mass spectrometry (CE-ESI-MS) was
used. A partial filling technique was used to avoid the CS entering the MS ion source.
Three different CDs: HP-β-CD, CM-β-CD and SBE-β-CD were tested as CSs; a volatile
BGE composed of ammonium acetate at pH 4.0 was used. Initially, an FFD was used to
investigate the significance of selected factors, and some center point measurements were
also performed to assess the curvature of the model. Since significant non-linear terms
were found, the FFD was completed with axial points to obtain a FCCD. The same type
of experimental matrix was performed in the case of all the three CDs. CD concentration,
percentage of capillary filled with CS and drying gas nebulization pressure were the factors
taken into consideration; chiral resolution, apparent selectivity and migration time were set
as responses. CD concentration and gas nebulization pressure had a significant effect on
the quality of the separation. Response surfaces were drawn from the mathematical model
and optimum experimental conditions were set to allow the robustness of the method [110].
3.3. Micellar Electrokinetic Chromatography (MEKC)
In MEKC the separations are achieved in the presence of surfactants supplemented to
the electrolyte solution at micellar concentration. Using ionic surfactants, the applicability
of CE is extended to neutral molecules thanks to their differential distribution between
the ionic micellar phase and the aqueous phase. When achiral surfactants are used, that is
most of the cases, direct enantioseparation can only be achieved including the CS to the
micellar BGE. The obtained mixed organized media represent intriguing systems because
of the possibility for multiple interactions i.e., between the solute enantiomers with the
CS and the micellar phase as well as between the latter and the CS. In these complex
systems, including in DoE variables such as nature and concentration of the surfactant, is
of primary importance.
Wan et al. applied two approaches for the chiral separation of 19 amino acids
by CE; an indirect separation of diastereomers formed by derivatization with (+)- or
(−)-l-(9-fluorenyl)ethyl chloroformate (FLEC—used as derivatization agent) and a direct
chiral separation after derivatization with 9-fluorenylmethyl chloroformate (FMOC). In
both cases, MEKC methods were applied for the separation. The analytical conditions
were optimized using an FFD. In the indirect separation, sodium dodecyl sulphate (SDS)
concentration and BGE pH, while in the direct separation isopropanol concentration, β-CD
concentration and SDS concentration were optimized using the experimental design. The
analytical performances of the indirect method proved to be superior, offering higher
separation efficiency [111].
Orlandini et al. developed a CE chiral separation method for the simultaneous
determination of the enantiomeric purity of ambrisentan, including three additional achiral
impurities. A MEKC method was applied, using SDS as surfactant and γ-CD as CS. The
effect of BGE concentration, BGE pH, γ-CD concentration, SDS concentration, temperature,
voltage and capillary length on chiral resolution and analysis time was investigated using
a screening asymmetric matrix. A FCCD was further used for optimization purposes,
studying the effect of significant factors (BGE pH, γ-CD concentration, voltage) on the
separation. The CE approach was developed inside the QbD framework, with the goal of
creating a DS where analysis results fulfil predetermined quality features with a certain
degree of probability. The DS was defined in combination with Monte-Carlo simulations.
The robustness of the method was verified using a PBD. The method was validated and
applied for the determination of ambrisentan in coated tablets [112]. The method can
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be highlighted because it is an example of how CE can be used for the simultaneous
determination of enantiomeric purity and of related substances of a pure enantiomer drug.
A MEKC method was developed by Flor et al. for the chiral purity control of mon-
telukast, a leukotriene antagonist receptor used in the treatment of asthma. The method al-
lows the simultaneous determination of R-trans-montelukast, its distomer
(S-trans-montelukast), diasteroisomers (R,S-cis forms), and its main degradation com-
pound, montelukast sulfoxide. A dual CD system composed of HTM-β-CD and SBE-β-CD
was employed in the separation. In the optimization step, the influence of BGE pH and
voltage was carried out using a FFD with two factors at three levels, followed by analyzing
the temperature by a OFAT approach. This was an uncommon optimization strategy
since it was carried out in two steps: in the first, the optimization was performed using
a multivariate technique, and in the second, using a univariate technique. Moreover, if
temperature had been taken into consideration in the original FFD, the algorithm may have
used a multivariate technique to execute the optimization stage. Moreover, important fac-
tors for enantioseparation as CS concentration have not been selected for the multivariate
approach. Robustness was evaluated using a PBD. The method allows the determination of
0.02% enantiomeric and diasteroisomeric impurities, and 0.01% montelukast sulfoxide. The
method was used for the determination of chiral purity of montelukast in bulk substances
and pediatric pharmaceutical forms [113].
Niedermeier and Scriba developed a CE method for the simultaneous determination
of the chiral impurity dextromepromazine and the oxidation product levomepromazine
sulfoxide in levomepromazine samples. Levomepromazine possesses an R-configuration
and is used as pure enantiomer as antipsychotic. Hydroxypropyl-γ-CD (HP-γ-CD) was the
selected CS and a FrFD was used for the optimization of BGE concentration, BGE pH, HP-
γ-CD concentration, temperature, and voltage. A FCCD was applied as response surface
methodology for deriving the design space by Monte Carlo simulations. Robustness was
estimated by means of a PBD. The method was applied for the determination of the analyte
in a commercial injection solution [114].
3.4. Non-Aqueous Capillary Electrophoresis (NACE)
In NACE pure organic solvents or their mixtures are employed in the preparation
of running BGE, to improve the solubility of hydrophobic analytes and/or to acquire
particular selectivity due to the effect of the solvents on the solutes’ acid-base characteristics.
There are some specific constraints in the development of chiral NACE methods, e.g., the
CS has to be soluble in the selected solvent and its ability to establish interactions with
the solutes, must not be compromised by the presence of the organic solvent. This could
be the case of CDs whose hydrophobic cavity can be overridden by the organic solvent
and no longer accessible to the solutes. On the other hand, in NACE, often solvents with
lower dielectric constants with respect to water, are used thus favoring the interactions
between the entities involved in the separation process. Under these conditions, the
(enantio)selectivity can be favorably tuned by the use of additives as supplementary
components of the BGE.
Servais et al. studied the influence of the nature of the cationic (ammonium, potas-
sium, sodium) and anionic (chloride, formate, camphorsulfonate, methanesulfonate) BGE
components as well as the concentration of HDMS-β-CD on the chiral resolution of 6 basic
analytes (three β-blockers: atenolol, celiprolol, propranolol; three local anesthetics: bupiva-
caine, mepivacaine, prilocaine) using NACE. Two D-oDs were used in the optimization
process. Both cationic and anionic BGE components had a significant impact on the enan-
tiomeric resolution of the analytes, although the cationic component exerted the greatest
influence. A NACE system was recommended for the separation, namely ammonium for-
mate and potassium camphorsulfonate in a methanolic solution containing HDMS-β-CD
and acidified with formic acid [115].
NACE was applied by Marini et al. for the determination of R-timolol as chiral
impurity in S-timolol maleate samples. Timolol is the only β-blocker used in therapy
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as pure enantiomer, in the form of S-timolol, in the treatment of glaucoma. DoE was
used for robustness testing and uncertainty assessment from quantitative data. The study
was based on the results of a previously published method by Marini et al., in which
timolol enantioresolution was achieved using HDMS-β-CD as CS and potassium camphor-
sulphonate in methanol acidified with formic acid as BGE [116]. One qualitative and six
quantitative parameters were investigated using a PBD. Resolution, migration times, and
relative migration times to pyridoxine (internal standard) were investigated as qualitative
responses for electrophoretic performance, while the content of R-timolol in S-timolol
maleate sample was evaluated as a quantitative response. The selected parameters had no
significant effect on the quantitative result, indicating the procedure’s robustness; however,
diverse HDMS-β-CD batches have been observed to have an impact on both qualitative
and quantitative outcomes [117].
In another study, the separation of 10 β-blockers (acebutolol, atenolol, betaxolol,
celiprolol, metoprolol, oxprenolol, pindolol, propranolol, sotalol, timolol) using HDMS-
β-CD and HDAS-β-CD as CS was investigated by Rousseau et al. A D-oD was applied
in method development; the experimental design involved two quantitative (BGE and
CD concentration) and two qualitative (BGE anion and CD nature) factors; while BGE
counter-ion, temperature, voltage, and formic acid concentration were kept constant. Chiral
resolution, mobility difference and selectivity were selected as analytical responses. Both
CD type and concentration were shown to have a substantial impact on the enantiomeric
resolution for all analytes. HDAS-β-CD was found to have a higher enantioresolution
ability than HDMS-β-CD for most analytes. All compounds had the best enantioseparation
in the presence of a high CD concentration, and most of them in the presence of a low BGE
anion concentration. A generic NACE system using methanol as the solvent, was proposed
for the enantioseparation of all analytes; to confirm the suitability of the technique, the
optimal experimental conditions were compared to the conditions obtained by modelling
mobility difference and selectivity [118].
The same research group published later a study regarding the development of a
generic CD system for the enantioseparation of basic drugs by NACE in acidifies methanol,
using heptakis(2-O-methyl-3-O-acetyl-6-O-sulfo)-β-CD (HMAS-β-CD) as CS. Four imi-
dazole antifungal agents (econazole, isoconazole, miconazole, sulconazole), three local
anesthetics (bupivacaine, mepivacaine, prilocaine), two sympathomimetics (salbutamol
and terbutaline) and one β-blocker (carvedilol) were selected as basic model analytes.
The effect of CD and BGE anion concentrations, as well as the type of the BGE anion,
on the chiral resolution was examined by D-oD; CD concentration was shown to have a
substantial impact on the chiral resolution. A NACE system based on HMAS-β-CD was
proposed and compared to both previous systems using HDAS-β-CD or HDMS-β-CD. A
fast method development strategy based on HMAS-β-CD was applied for the enantiosepa-
ration of ketamine, and its metabolite norketamine, after in vitro metabolism (incubation
of ketamine in phenobarbital-induced male rat liver microsomes systems) [119].
Niedermaier and Scriba developed a NACE method using methanol as the medium
for the chiral separation of four phenothiazine derivatives (alimerazine, mepromazine,
promethazine, thioridazine). HDAS-β-CD, HDMS-β-CD and octakis(2,3-di-O-methyl-6-
O-sulfo)-γ-CD (ODMS-γ-CD) proved to be effective CSs for mepromazine, promethazine
and alimemazine, while thioridazine was only partially resolved by using SBE-β-CD. In
the same study a NACE method for the determination of dextromepromazine as chiral
impurity of levomepromazine was developed employing QbD principles. HDMS-β-CD
was used as CS and a FrFD was developed for evaluating the knowledge space, followed
by a FCCD for further method optimization; the DS was configured using Monte Carlo
simulations. Robustness of the method was verified using a PBD. The validated method
was applied in chiral purity determination of levomepromazine in bulk substance and
tablets. The assay was used also to detect levomepromazine sulfoxide, albeit quantification
was impeded by the second migrating diastereomer’s poor peak shape [120].
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3.5. Capillary Electrochromatography (CEC)
In CEC the capillary is filled with a stationary phase; once the selected electrolyte
solution is loaded and an appropriate conditioning is performed, the applied electric field
results in EOF which will pump the electrolyte solution through the capillary column
similarly to the mobile phase in HPLC. The analytes are separated according to the com-
bined effects of the interactions with the chromatographic phase and on the basis of their
electrophoretic mobility.
Chiral separation of 25 model compounds (neutral, acidic, basic) was carried out
by Karlsson et al. using aqueous and non-aqueous CEC and a glycopeptide antibiotic,
teicoplanin, as CSP. The impact of non-aqueous PO mobile phase parameters on the EOF,
chiral resolution, and peak efficiency was evaluated using a DoE strategy for two model
compounds (metoprolol, terbutaline); the methanol content of the mobile phase proved to
be the most important factor for obtaining high values of the selected responses. Teicoplanin
CSP proved to be a good solution in CEC in reversed phase (RP) and PO conditions for the
enantioseparation of a high number of pharmaceuticals [121].
Wikström et al. published a CEC study, in which another glycopeptide antibiotic,
vancomycin, was used as CSP covalently bonded to LiChrospher®diol silica packed column
both in the RP and PO mode. A DoE strategy was used to determine the optimum PO phase
composition, which indicated that organic modifier content ratio (methanol, acetonitrile)
has a significant effect on resolution and peak efficiency. Thalidomide was considered as
model molecule during the study; after optimization, the method was used to separate
several basic analytes including four β-blocking agents (alprenolol, atenolol, metoprolol,
practolol) in PO mode [122].
A generic experimental strategy for the enantioseparation of 15 acidic drugs by CEC
using polysaccharide CSPs was developed by Mangelings et al. Four CSPs were tested:
Chiralcel OD-RH, Chiralcel OJ-RH, Chiralpak AD-RH and Chiralpak AS-RH. The studied
factors included BGE concentration, BGE pH, acetonitrile content of the mobile phase, volt-
age, temperature; chiral resolution and analysis time were set as responses [123]. Starting
with a general screening experiment, the study was built on a concept of a decision tree.
A screening process for the four CSPs was established, based on the idea that majority of
enantioselectivity will be visible in the initial trial. A three-level four-factor well-balanced
design derived from a PBD and proposed by Vander Heyden et al. was used [124]. How-
ever, the addition of voltage to the initial design as the fifth factor increased the number of
experiments from 9 to 27. A proper choice of the screening design (FrFD) could probably
have provided the same efficiency but in fewer experiments. The authors pointed out the
fact that if baseline separation is seen during screening, an optimization phase could be
useful to enhance resolution and/or reduce analysis time.
Table 1 presents chronologically a list of chiral CE methods for the analysis of certain
pharmaceuticals developed by using DoE strategies.
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Table 1. Chiral CE methods for the analysis of pharmaceuticals developed by using experimental design strategies.
Analytes Sample Experimental Design Type Factors Responses Optimized Conditions References
Clenbuterol bulk substance PBD




number of theoretical plates
0.1 M citric acid/0.2 M phosphate
BGE, pH 4.0, 16 mM β-CD, 19 ◦C,
13 kV, 214 nm
[47]
Amlodipine bulk substance CCD BGE pH, CD concentration,temperature
resolution, Kaiser peak
separation function
50 mM phosphate BGE, pH 3.16,




(levofenfluramine) bulk substance PBD





100 mM phosphate BGE, pH 3.0,
10 mM DM-β-CD, 40% methanol,
20 ◦C, 25 kV, 214 nm
[50]
Amphetamines (amphetamine,
methamphetamine, MDA, MDMA, MDEA) bulk substance CCD





118 mM phosphate BGE, pH 3.5,
16 mM HP-β-CD, 28 ◦C, 25 kV,
200 nm
[51]
Epinephrine bulk substance FrFDCCD





111 mM phosphate BGE, pH 7.0,
9 mM CM-β-CD, 20 ◦C, 18 kV,
206 nm
[52]
Imidazole derivatives (bifonazole, econazole,
miconazole, sulconazole) bulk substance FrFD
BGE pH, acetonitrile concentration,
CD concentration, temperature
resolution, migration time,
number of theoretical plates
100 mM phosphate BGE, pH 4.70,
5.2% acetonitrile, 5.80 mM β-CD,
35 ◦C, 30 kV, 230 nm
[53]
Celiprolol bulk substance, tablet,urine FCCD




52 mM acetate BGE, pH 4.0, 3 mM
S-β-CD, 19.5 ◦C, 30 kV, 220 nm [55]
Salbutamol spiked urine PBDDD
BGE concentration, BGE pH, CS
concentration, methanol
concentration, voltage
BGE pH, CS concentration, voltage
resolution, migration time
30 mM Tris BGE, pH 5.3, 1.75%
dermatan sulphate, 5% methanol,
15 ◦C, 24 kV, 220 nm
[59]
Atropine ophthalmic solution, plantextract CCD




55 mM phosphate BGE, pH 7.0,
2.9 mM S-β-CD, 20 ◦C, 20 kV,
195 nm
[60]
Methadone bulk substance FFDFCCD
CD concentration, percentage of
capillary filled with CD, gas
nebulization pressure
resolution
CE-ESI-MS: 20 mM ammonium
acetate BGE, pH 4.0, 18 mg/mL
HP-β-CD/ 0.25 mg/mL CM-β-CD/















200 mM phosphate BGE, pH 6.0,
413 mM HP-β-CD, 20 ◦C,−20 kV,
200 nm
[63]




difference in effective mobility
15 mM bistris-acetate, pH 6.5,
31.2 µM Cel7A, 17% (v/v)
acetonitrile, 22 ◦C, 20 µA, 200 nm
[64]
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Table 1. Cont.
Analytes Sample Experimental Design Type Factors Responses Optimized Conditions References
2-[(4′-benzoyloxy-2′-hydroxy)phenyl-propionic
acid] bulk substance CCD
CS concentration, BGE pH,
temperature resolution, migration time
50 mM Britton-Robinson BGE, pH
6.4, 7 mM vancomycin, 22 ◦C, 20 kV,
195 nm
[65]
Ofloxacin bulk substance FCCD BGE concentration, BGE pH, CDconcentration, temperature
resolution, migration time,
peak area, current
50 mM phosphate BGE, pH 2.8, 4%
(w/v) M-β-CD, 25 ◦C, 20 kV, 280 nm [66]
Ketamine injection solution PBDCCD
BGE concentration, BGE pH, CD
concentration, methanol
concentration, voltage
BGE pH, methanol concentration
resolution
50 mM phosphate BGE, pH 5.20, 2%
(w/v) CM-β-CD, 30% methanol,







temperature resolution, migration time
100 mM Tris BGE, pH 2.5, 0.15%
(w/v) S-β-CD, 25 ◦C, 25 kV, 210 nm [75]




80 mM phosphate BGE, pH 2.5,
37 mM HP- β-CD, 3.7% S-α-CD,
25 ◦C, 20 kV, 270 nm
[76]
S-Citalopram–chiral purity (R-Citalopram) bulk substance, tablets FCCD BGE concentration, CD2concentration, voltage, temperature
resolution, migration time,
current
20 mM phosphate BGE, pH 2.5,
0.5 mg/mL β-CD, 22 mg/mL
S-α-CD, 28 ◦C, −20 kV, 205 nm
[77]
Propranolol, 4-hydroxypropranolol bulk substance BBD BGE concentration, BGE pH, CDconcentration, voltage resolution, migration time
25 mM triethylamine/phosphate
BGE, pH 9.0, 4% (w/v) CM-β-CD,
25 ◦C, 17 kV, 208 nm
[78]
Zopiclone bulk substance, tablets FFD BGE concentration, BGE pH, CDconcentration, voltage resolution, migration time
60.2 mM phosphate BGE, pH 2.0,
1 M urea, 20 mM β-CD, 25 ◦C,
30 kV, 215 nm
[79]
Clopidogrel (chiral purity R-clopidogrel) bulk substance reduced CCD BGE concentration, BGE pH, CDconcentration, voltage resolution, migration time
10 mM triethylamine–phosphoric
acid BGE, pH 2.3, 5% S-β-CD, 20 ◦C,
−12 kV, 195 nm
[80]
Dapoxetine bulk substance OAD




70 mM acetate BGE, pH 4.5, 3 mM
M-γ-CD, 20% (v/v) methanol,
15 ◦C, 15 kV, 215 nm
[82]
Magnesium-L-aspartate (chiral purity
D-aspartate) bulk substance, tablets FFD
BGE concentration, BGE pH, CD
concentration resolution, migration time
50 mM phosphate, pH 7, 18 mM
HP-β-CD, 18% (v/v) DMSO, 20 ◦C,
30 kV, LIF detection
[87]
Asenapine bulk substance OAD
BGE concentration, BGE pH, CD
concentration, methanol
concentration, temperature, voltage
resolution 160 mM Tris-acetate BGE, pH 3.5,7 mM β-CD, 20 ◦C, 15 kV, 214 nm [89]
Pomalidomide bulk substance OAD BGE concentration, BGE pH,temperature, voltage resolution
50 mM Tris-acetate BGE, pH 6.5,
15 mM CM-β-CD, 20 ◦C, 15 kV,
215 nm
[90]
Lenalidomide (chiral purity R-lenalidomide) bulk substance FCCD BGE concentration, temperature,voltage resolution
30 mM phosphate BGE, pH 6.5,
30 mM SBE-β-CD, 10 ◦C, 12 kV,
210 nm
[91]
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Table 1. Cont.
Analytes Sample Experimental Design Type Factors Responses Optimized Conditions References
Vildagliptin (chiral purity R-vildagliptin) bulk substance, tablets OAD




75 mM Tris-acetate BGE, pH 4.75,
20 mM SBE-α-CD, 15 ◦C, 25 kV,
40 mbar × 4 s hydrodynamic
injection, 200 nm
[92]
Levosulpiride, (chiral purity R-sulpiride) bulk substance, tablets Asymmetric screening matrixDD
BGE concentration, BGE pH, type of
neutral cyclodextrin, charged CD
concentration, neutral CD
concentration, voltage
BGE pH, charged CD concentration,
neutral CD concentration, voltage
resolution, migration time
5 mM Britton-Robinson BGE, pH
3.45, 10 mM S-β-CD, 34 mM
M-β-CD, 16 ◦C, −14 kV, 214 nm
[88]
Ambrisentan (chiral purity R-ambrisentan) bulk substance, coatedtablets
Asymmetric screening matrix
FCCD




BGE pH, CD concentration, voltage
resolution, migration time
capillary total length 64.5 cm,
100 mM borate BGE, pH 9.20,
100 mM SDS, 50 mM γ-CD, 22 ◦C,
30 kV, 200 nm
[112]
S-Ambrisentan (chiral purity R-ambrisentan) bulk substance FrFDFCCD




resolution, migration time 50 mM sodium acetate BGE, pH 4.0,30 mM γ-CD, 25 ◦C, 25 kV, 200 nm [93]
Montelukast (chiral purity R-trans-montelukast,
R,S-cis-montelukast, S,R-cis-montelukast)
bulk substance, chewable
tablets, oral granules FFD BGE concentration, voltage resolution
20 mM borate BGE, 10 mM SDS,
pH 9.0, 10 mM HTM-β-CD, 12 mM








BGE concentration, BGE pH, CD
concentration, temperature, voltage




100 mM citric acid BGE, pH 2.85,
3.6 mg/mL HP-γ-CD, 15 ◦C, 25 kV,
253 nm
[114]
S-Dapoxetine (chiral purity R-Dapoxetine) bulk substance, tablets FrFDFCCD
BGE concentra-tion, BGE pH,






50 mM phosphate BGE, pH 6.3,
45 mg/mL S-γ-CD, 40.2 mg/mL
DM-β-CD, 15 ◦C, 9 kV, 215 nm
[83]
Sitafloxacin, chiral impurities bulk substance FrFDFCCD




BGE pH, CD concentration, Cu2+
concentration, D-Phe concentration
resolution, migration time
15 mM phosphate BGE, pH 4.5,
15 mM D-Phe, 20 mM CuSO4,
20 mM γ-CD, 25 ◦C, 15 kV, 297 nm
[94]
Fluoxetine bulk substance, tablets OAD




50 mM phosphate BGE, pH 5.0,
10 mM HTM-β-CD, 15 ◦C, 20 kV,
50 mbar × 1 s hydrodynamic
injection, 230 nm
[95]
Pregabalin bulk substance, capsules D-oDFCCD





100 mM phosphate BGE
concentration, pH 2.5, 40 mg/mL
HTM-β-CD, 25 ◦C, 15 kV, 220 nm
[96]
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Dexmedetomidine (chiral purity
R-medetomidine) bulk substance, tablets
FrFD
FCCD






50 mM phosphate BGE, pH 6.5,
40 mg/mL S-β-CD, 17 ◦C, 10 kV,
200 nm
[97]
Dextrometorphan (chiral purity R-metorphan) bulk substance, tablets FrFDFCCD




30 mM phosphate BGE, pH 6.5,
16 mg/mL S-β-CD, 14 mg/mL
M-α-CD, 20 ◦C, 20 kV, 200 nm
[98]
Cinacalcet (chiral purity S-cinacalcet) bulk substance, tablets BBD BGE pH, CD concentration,methanol concentration, voltage resolution, migration time
150 mM phosphate BGE, pH 2.7,
3.1 mM HP-γ-CD, 2% (v/v)
methanol, 18 ◦C, 26 kV, 220 nm
[99]
Benzodiazepines (lorazepam, lormetazepam,
oxazepam, temazepam) bulk substance FrFD




20 mM borate BGE, pH 9.0, 5%
HES-β-CD, 15% methanol, 15 ◦C,
20 kV, 230 nm
[100]
Lansoprazole, Rabeprazole bulk substance, capsules FrFDCCD





Lansoprazole: 25 mM phosphate
BGE, pH 7.0, 10 mM SBE-β-CD,
20 mM γ-CD, 17 ◦C, 20 kV, 210 nm
Rabeprazole: 25 mM phosphate
BGE, pH 7.0, 15 mM SBE-β-CD,













25 mM phosphate BGE, pH 7.0,
23.5 mg/mL S-β-CD, 10% (v/v)
2-propanol, 16.3 ◦C, 16.5 kV, 200 nm
[106]
Levomepromazine (chiral purity









750 mM acetic acid, 55 mM
ammonium acetate in methanol
BGE, 27.5 mg/mL HDMS-β-CD,
15 ◦C, 22 kV, 250 nm
[120]
Tramadol bulk substance, capsules FCCD BGE pH, CD concentration,temperature resolution, migration time
25 mM tetraborate BGE, pH 11.0,
5 mM CM-β-CD, 15 ◦C, 17.5 kV,
210 nm
[105]
Amlodipine bulk substance, tablets OAD




25 mM phosphate BGE, pH 9.0,
15 mM CM-β-CD, 15 ◦C, 25 kV,
30 mbar × 1 s hydrodynamic
injection, 230 nm
[107]
Citalopram bulk substance, tablets FrFDFCCD






25 mM phosphate BGE, pH 7.0,
3 mM CM-β-CD, 17.5 ◦C, 15 kV,
50 mbar injection pressure, 230 nm
[108]
Venlafaxine bulk substance, capsules FCCD CD concentration, temperature,voltage resolution, migration time
25 mM phosphate BGE, pH 2.5,
10 mM CM-β-CD, 15 ◦C, 25 kV,
230 nm
[109]
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4. Discussion
Given the advantages of using DoE strategies in the development and optimization of
CE enantioselective methods, it is surprising that they haven’t been used more extensively.
The relatively low number of applications of DoE in the development and optimization
of CE chiral methods in the late 90′ and early 2000′ could be explained due to a lack of
knowledge and access to specialized software. However, a clear tendency of applying
multivariate approaches in CE chiral method development can be observed in the last
ten years. It can be noted that DoE was implemented mostly in the development and
optimization of CZE methods (as it is the most frequently used CE technique), and only in
few NACE, CEC, MEKC and CE-MS methods.
Initial studies often employed a single design to establish the optimum analytical
conditions, often in combination with an OFAT approach, while the current trends head
towards the use of a screening design to identify significant experimental factors followed
by an optimization design for fine-tuning the separation conditions. The latter strategy in
most cases deserves to be preferred, being more reliable and effective. First, it enables to
consider all the possible critical parameters, without the need to choose which parameters
should be fixed or studied when carrying out optimization by RSM. Moreover, another
advantage is the possibility of moving the experimental domain of some factors towards
the zone leading to the best results, as the outcome of the screening phase. With this
approach it is also possible to ward off some questionable procedures which nevertheless
can be found in the literature, such as the introduction of further factors to be studied by
OFAT after having completed the multivariate optimization.
Many variables can affect CE chiral separations, and this is critical in obtaining
enantioresolution. In this regard, application of DoE is well suited for the development
of enantioresolution methods because they provide an effective strategy for clarifying the
impact of experimental conditions. Each design has its own set of features that can be used
to meet specific requirements.
It is worth to be mentioned, that scouting experiments should precede the DoE strategy,
in order to establish some basic experimental parameters, as well as the CE operative mode,
and to assess the experimental domain. For example, the type of CS is typically selected in
this early phase of method development.
In a recent review by Yu and Quirino [7], the CSs used in EKC have been grouped into:
(a) macromolecular (including macrocyclic), (b) supramolecular, and (c) low molec-ular
mass compounds, showing the vast choice of opportunities to face the enantiosepa-ration
challenge. In the selection of the suitable CS, that is the first step towards in meth-od
optimization, a rational approach should be desirable, and in the recent years a notable
number of studies have involved molecular modelling and/or NMR to understand the
chiral recognition mechanism of CSs. In some specific cases, the achieved information
has allowed for the enantioselectivity of the CS towards a chiral analyte, to be predicted.
Moreover, by means of the described approach, the classes of analytes that can be separated
by a given CS could be predicted as well. Nevertheless, the choice of the suitable CS for
each target, is usually still carried out by trial and error approach. Generally, a screening
of different CD derivatives (neutral and negatively/positively charged) at several pH
values (where the analyte is found under ionized and/or unionized form) is performed.
The optimal CS is then selected based on resolution, analysis time, peak shape, or other
quality characteristics of the separation system. Importantly, this strategy must be critically
approached by the researcher which should deeply know all of the characteristics of the
analyte (e.g., molecular mass, hydrophobicity, pKa value/s etc.) in order to restrict the
number of potentially useful CSs for the considered purpose. However, sometimes the
type of the CS can be introduced as qualitative factor in the screening design; this can
be advantageous, because the enantioseparation power of the CS can be tuned by the
other experimental conditions and in this way a complete and systematic overview of the
candidate selectors can be obtained.
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Usually in chiral CE applied DoE, the experimental variables are BGE concentration,
BGE pH, CS concentration, temperature, voltage; while the responses are chiral resolution,
analysis time and sometimes generated current, peak symmetry, and efficiency. Typically,
a number of 4–7 factors is evaluated in the screening phase, while in the optimization
step the study is limited to 3–4 factors. It is fundamental to introduce in the screening all
the parameters that could influence the method, in order to investigate the effect of all of
them. The significant factors for a selected response are determined in the screening step.
The optimal conditions are determined by evaluating the effect of the selected significant
factors in the optimization step.
The analytical responses are usually chiral resolution and analysis time (migration
time of the second enantiomer), but sometimes other responses like peak shape, described
by values of peak efficiency (number of theoretical plates) and peak symmetry (peak
asymmetry factor, tailing factor) are also used. The choice of the responses is usually made
on the basis of the critical analytical issues which are evidenced in the first phase of method
development. Moreover, in many cases, additional quantitative responses as migration
times or peak areas are included in the robustness testing, factors which were not followed
during method optimization.
During the screening stage, the most significant factors are separated from those
that are thought to influence at a lesser extent the analytical responses. The factors that
do not provide useful information on the behavior of the responses must be eliminated
in this stage, leaving just the most important ones to be examined in the optimization
process. Among screening designs, FrFD, D-oD, and PBD are highly efficient choices
as they require fewer experiments than FFD. PBD is particularly attractive because it
requires few experiments, however it is used mainly in the validation process, to verify
method robustness, because it supports only two levels for each experimental factor. FrFD
represents the most frequently used solution in chiral CE methods screening phase, and
over half of the articles listed in Table 1 use this kind of design in the screening step.
After the significant factors have been identified, their influence on the analytical
responses must be studied in order to define the conditions leading to the desired response.
This phase involves creating a mathematical model which depicts the response’s behavior
as the levels of the factors change. In the optimization process, RSM has been widely used;
RSM aims to convert experimental data into a polynomial equation that best explains the
response’s behavior, allowing for trustworthy predictions. Several optimization designs
have been used, including CCD, OAD, BBD, or DD. CCD and especially FCCD is the
most employed design in optimization of chiral CE methods. The response surface is
estimated based on the design findings, allowing for the determination of optimal factor
conditions. The selection of the factors to be investigated and their levels is the initial step
of the optimization screening; only two or three variables are usually further optimized,
even if the optimization dealing with four factors can still be easily managed with a
reasonable number of experiments. In terms of the number of levels, three up to seven can
be considered, depending on the design that was used. In some studies, RSM was used
without performing a screening design, while the factors involved were selected based on
the results of preliminary analysis.
The experimental setting is then devised and carried out, and the responses are
measured. Following that, a polynomial model that explains the relationship between the
response and the factors is constructed. ANOVA significance and validity are assessed
together with the parameters describing the quality of the model in terms of fitting and
prediction. Only after that, the model is evaluated graphically and/or statistically. The
best experimental conditions are identified and experimentally tested in the last phase of
method optimization using a response surface design.
In general, for carrying out the multivariate optimization of CE methods the re-
searchers should be adequately trained in order to avoid pitfalls in the overall strategy.
As a matter of fact, anyone, having at disposal a DoE software, can plan an experimental
design, run the experiments, and obtain plots by graphical analysis of effects or by RSM.
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However, many issues can arise in the different steps of DoE workflow from a superficial
knowledge of multivariate techniques.
First of all, the researcher should be aware of the theoretical principles which lead
to the choice of the proper matrices according to their characteristics. A screening matrix
cannot be used for predictions or for drawing response surfaces; at the same time, an opti-
mization design without a proper selection of the variables made by a previous screening
phase could represent a waste of resources which could be better addressed.
Moreover, the researcher should carefully define the limits of the experimental domain
for the factors, and in most cases preliminary experiments are necessary for this choice.
In fact, it is important that all the planned experiments can be carried out in a safe zone,
where technical constraints do not occur, and all the considered responses can be measured.
The constraints can include, for instance, a too high value of generated current, or a too
low value of EOF for which the analytes cannot be drawn to the detector in a reasonable
time, or a too high value of CS concentration for which the BGE cannot be prepared in
practice. In order to be able to calculate the coefficients of the model, a sufficient number of
measured responses should be available; if this does not happen, the whole experimental
design can fail and a new one should be planned.
Another possible shrewdness for avoiding subsequent issues in data treatment is
to give a first critical look to the data before including the responses in the software for
calculating the model. In this way the researcher can identify the presence of inconsistent
data which can be derived from wrong calculation of the responses or from exchange of
rows in the matrix or simply from typing errors. These responses should be corrected in
order to avoid including wrong data; in fact, in some cases they could be evidenced as
outliers by the software, but if this does not happen, they contribute to the calculation of
the model and thus to misleading results.
Another point of paramount importance is that in the optimization phase the model
performances should be checked by calculation of ANOVA and of the model quality
parameters, and that these data should be reported in the developed method. This is a
step which is sometimes neglected by the researchers, but it has to be underlined that if
the model results of poor quality, it cannot be used for drawing response surfaces, and it
should be discarded.
Finally, the latest trends in the multivariate development of CE enantioseparation
methods regard the implementation of QbD principles. This science and risk-based ap-
proach consists in a well-defined framework where the key points are the use of risk
assessment tools, the multivariate study of the effect of critical process parameters, artic-
ulated in a screening and optimization phase, leading to the identification of the MODR
and finally to the definition of method control. The main novelty of this approach is that
the optimum is no more represented by a point, but by a multidimensional zone where
the quality of the analytical performances is assured with a selected probability. This
strategy can be particularly useful when the aim of the method is the routine control of
the enantiomeric purity of a drug administered as single enantiomer. By QbD, an in-depth
understanding of the interactions and of the criticality of procedure parameters can be
achieved. A higher confidence in the results is generated, with a wider knowledge and
an outcome represented by more robust methods and by a greater regulatory flexibility,
flexibility, since no revalidation of the method is required for changes within the MODR.
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Abbreviations
ANOVA Analysis of variance
AQbD Analytical Quality by Design
ASD Asymmetric screening design
BBD Box-Behnken design
BGE background electrolyte
CCC Central composite circumscribed design




CE-MS capillary electrophoresis—mass spectrometry
CE-ESI-MS capillary electrophoresis coupled with electrospray ionization mass spectrometry
CMA Critical Method Attribute
CMP Critical Method Parameter
CM-β-CD carboxymethyl-β-cyclodextrin
CPP critical process parameter
CQA critical quality attributes
CS chiral selector
CSP chiral stationary phase
CZE capillary zone electrophoresis
D-oD D-optimal design
D-Phe D-Phenylalanine




EMA European Medicines Agency
EOF electroosmotic flow
FDA Food and Drug Administration
FCCD Face centered central composite design
FFD Full factorial design
FLEC l-(9-fluorenyl)ethyl chloroformate
FMOC 9-fluorenylmethyl chloroformate











HSA human serum albumin
ICH International Council for Harmonisation
LIF laser induced fluorescence
LOD limit of detection
LOQ limit of quantification
M-α-CD methyl-α-cyclodextrin
M-β-CD methyl-β-cyclodextrin
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MEKC micellar electrokinetic chromatography
MODR Method operable design region
NACE nonaqueous capillary electrophoresis
OAD Orthogonal array design
ODMS-γ-CD octakis(2,3-di-O-methyl-6-O-sulfo)-γ-cyclodextrin




QbD Quality by Design
RP reverse phase




SDS sodium dodecyl sulfate
S/N signal-to-noise
SSD Symmetric screening design
SNRI serotonin and norepinephrine reuptake inhibitor
SSRI selective serotonin reuptake inhibitor
References
1. Brooks, W.H.; Guida, W.C.; Daniel, K.G. The significance of chirality in drug design and development. Curr. Top. Med. Chem.
2011, 11, 760–770. [CrossRef]
2. Calcaterra, A.; D’Acquarica, I. The market of chiral drugs: Chiral switches versus de novo enantiomerically pure compounds. J.
Pharm. Biomed. Anal. 2018, 147, 323–340. [CrossRef]
3. Ward, T.J.; Ward, K.D. Chiral separations: A review of current topics and trends. Anal. Chem. 2012, 84, 626–635. [CrossRef]
[PubMed]
4. Chankvetadze, B. Contemporary theory of enantioseparations in capillary electrophoresis. J. Chromatogr. A 2018, 1567, 2–25.
[CrossRef]
5. Krait, S.; Konjaria, M.L.; Scriba, G.K.E. Advances of capillary electrophoresis enantioseparations in pharmaceutical analysis
(2017–2020). Electrophoresis 2021. [CrossRef]
6. Fanali, S.; Chankvetadze, B. Some thoughts about enantioseparations in capillary electrophoresis. Electrophoresis 2019, 40,
2420–2437. [CrossRef]
7. Yu, R.B.; Quirino, J.P. Chiral Selectors in Capillary Electrophoresis: Trends during 2017–2018. Molecules 2019, 24, 1135. [CrossRef]
8. Pharmacopoeial Discussion Group. European Pharmacopoeia, 10th ed.; Council of Europe: Strasbourg, France, 2020.
9. Fukuda, I.M.; Pinto, C.F.F.; Moreira, C.D.S.; Saviano, A.M.; Lourenço, F.R. Design of experiments (DoE) applied to pharmaceutical
and analytical quality by design (QbD). Braz. J. Pharm. Sci. 2018, 54, 1–16. [CrossRef]
10. Sangshetti, J.N.; Deshpande, M.; Zaherr, Z.; Shinde, D.B.; Arote, R. Quality by design approach: Regulatory need. Arab. J. Chem.
2017, 10, 3412–3425. [CrossRef]
11. Politis, S.N.; Colombo, P.; Colombo, G.; Rekkas, D.M. Design of experiments (DoE) in pharmaceutical development. Drug. Dev.
Ind. Pharm. 2017, 43, 889–901. [CrossRef]
12. Siouffi, A.M.; Phan-Tan-Luu, R. Optimization methods in chromatography and capillary electrophoresis. J. Chromatogr. A 2000,
892, 75–106. [CrossRef]
13. Sentellas, S.; Saurina, J. Chemometrics in capillary electrophoresis. Part A: Methods for optimization. J. Sep. Sci. 2003, 26, 875–885.
[CrossRef]
14. Sentellas, S.; Saurina, J. Chemometrics in capillary electrophoresis. Part B: Methods for data analysis. J. Sep. Sci. 2003, 26,
1395–1402. [CrossRef]
15. Hanrahan, G.; Montes, R.; Gomez, F.A. Chemometric experimental design-based optimization techniques in capillary elec-
trophoresis: A critical review of modern applications. Anal. Bioanal. Chem. 2008, 390, 169–179. [CrossRef] [PubMed]
16. Orlandini, S.; Gotti, R.; Furlanetto, S. Multivariate optimization of capillary electrophoresis methods: A critical review. J. Pharm.
Biomed. Anal. 2014, 87, 290–307. [CrossRef]
17. Bezerra, M.A.; Santelli, R.E.; Oliveira, E.P.; Villar, L.S.; Escaleira, L.A. Response surface methodology (RSM) as a tool for
optimization in analytical chemistry. Talanta 2008, 76, 965–977. [CrossRef]
18. Vera Candioti, L.; De Zan, M.M.; Cámara, M.S.; Goicoechea, H.C. Experimental design and multiple response optimization.
Using the desirability function in analytical methods development. Talanta 2014, 124, 123–138. [CrossRef]
19. Eriksson, L.; Johansson, E.; Kettaneh-Wold, N.; Wikström, C.; Wold, S. Design of Experiments-Principles and Applications, 3rd ed.;
Umetrics AB: Umeå, Sweden, 2008.
Molecules 2021, 26, 4681 36 of 40
20. ICH. ICH Harmonised Tripartite Guideline; Validation of Analytical Procedures: Text and Methodology Q2(R1) International Council for
Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; ICH: Geneva, Switzerland, 2005.
21. Brynn Hibbert, D. Experimental design in chromatography: A tutorial review. J. Chromatogr. B 2012, 910, 2–13. [CrossRef]
22. Montgomery, D.C. Design and Analysis of Experiments, 4th ed.; John Wiley & Sons: New York, NY, USA, 1997.
23. Dejaegher, B.; Mangelings, D.; Heyden, Y.V. Experimental design methodologies in the optimization of chiral CE or CEC
separations: An overview. Methods Mol. Biol. 2013, 970, 409–427. [CrossRef]
24. Massart, D.L.; Vandeginste, B.G.M.; Buydens, L.M.C.; De Jong, S.; Lewi, P.J.; Smeyers-Verbeke, J. Handbook of Chemometrics and
Qualimetrics: Part. A, 1st ed.; Elsevier Science B.V.: Amsterdam, The Netherlands, 1997.
25. Dejaegher, B.; Vander Heyden, Y. Experimental designs and their recent advances in set-up, data interpretation, and analytical
applications. J. Pharm. Biomed. Anal. 2011, 56, 141–158. [CrossRef]
26. Goupy, J.L. Methods for Experimental Design, 1st ed.; Elsevier Science Publishers B.V.: Amsterdam, The Netherlands, 1993.
27. Lee, R. Statistical design of experiments for screening and optimization. Chem. Ing. Tech. 2019, 91, 191–200. [CrossRef]
28. Lundstedt, T.; Seifert, E.; Abramo, L.; Thelin, B.; Nyström, A.; Pettersen, J.; Bergman, R. Experimental design and optimization.
Chemom. Intell. Lab. Syst. 1998, 42, 3–40. [CrossRef]
29. Deming, S.N.; Morgan, S.L. Experimental Design: A Chemometric Approach, 2nd ed.; Elsevier Science Publishers B.V.: Amsterdam,
The Netherlands, 1993.
30. Ranade, S.S.; Thiagarajan, P. Selection of a design for response surface. IOP Conf. Ser. Mater. Sci. Eng. 2017, 263, 022043. [CrossRef]
31. Brereton, R.G. Chemometrics-Data Analysis for the Laboratory and Chemical Plant, 1st ed.; John Wiley & Sons Ltd.: Chichester,
UK, 2003.
32. Atkinson, A.C.; Donev, A.N. Optimum Experimental Designs; Oxford Science Publications: Oxford, UK, 1992.
33. De Aguiar, P.F.; Bourguignon, B.; Khots, M.S.; Massart, D.L.; Phan-Than-Luu, R. D-optimal designs. Chemom. Intell. Lab. Syst.
1995, 30, 199–210. [CrossRef]
34. Siebertz, K.; van Bebber, D.; Hochkirchen, T. Grundlagen. In Statistische Versuchsplanung; Springer: Berlin/Heidelberg,
Germany, 2010.
35. ICH. ICH Harmonised Tripartite Guideline. Pharmaceutical Development Q8(R2) International Council for Harmonisation of Technical
Requirements for Pharmaceuticals for Human Use; ICH: Geneva, Switzerland, 2009.
36. ICH. ICH Harmonised Tripartite Guideline. Quality Risk Management Q9 International Council for Harmonisation of Technical Require-
ments for Pharmaceuticals for Human Use; ICH: Geneva, Switzerland, 2005.
37. ICH. ICH Harmonised Tripartite Guideline. Pharmaceutical Quality System Q10 International Council for Harmonisation of Technical
Requirements for Pharmaceuticals for Human Use; ICH: Geneva, Switzerland, 2008.
38. ICH. ICH Harmonised Tripartite Guideline. Development and Manufacture of Drug Substances Q11 International Council for Harmonisation
of Technical Requirements for Pharmaceuticals for Human Use; ICH: Geneva, Switzerland, 2012.
39. Borman, P.; Nethercote, P.; Chatfield, M.; Thompson, D.; Truman, K. The application of Quality by Design to Analytical Methods.
Pharm. Tech. 2007, 31, 142–152.
40. Vogt, F.G.; Kord, A.S. Development of Quality-By-Design Analytical Methods. J. Pharm. Sci. 2011, 100, 797–812. [CrossRef]
[PubMed]
41. Rozet, E.; Lebrun, P.; Debrus, B.; Boulanger, B.; Hubert, P. Design Spaces for analytical methods. Trends Anal. Chem. 2013, 42,
157–167. [CrossRef]
42. Orlandini, S.; Pinzauti, S.; Furlanetto, S. Application of quality by design to the development of analytical separation methods.
Anal. Bioanal. Chem. 2013, 405, 443–450. [CrossRef]
43. Deidda, R.; Orlandini, S.; Hubert, P.; Hubert, C. Risk-based approach for method development in pharmaceutical quality control
context: A critical review. J. Pharm. Biomed. Anal. 2018, 161, 110–121. [CrossRef]
44. Dispas, A.; Avohou, H.T.; Lebrun, P.; Hubert, P.; Hubert, C. ‘Quality by Design’ approach for the analysis of impurities in
pharmaceutical drug products and drug substances. Trends Anal. Chem. 2018, 101, 24–33. [CrossRef]
45. Derringer, G.; Suich, R. Simultaneous optimization of several response variables. J. Qual. Technol. 1980, 12, 214–219. [CrossRef]
46. Altria, K.D.; Goodall, D.M.; Rogan, M.M. Chiral separation of β-amino alcohols by capillary electrophoresis using cyclodextrins
as buffer additives. I. Effect of varying operating parameters. Chromatographia 1992, 34, 19–24. [CrossRef]
47. Rogan, M.M.; Altria, K.D.; Goodall, D.M. Plackett-Burman experimental design in chiral analysis using capillary electrophoresis.
Chromatographia 1994, 38, 723–729. [CrossRef]
48. Small, T.S.; Fell, A.F.; Coleman, M.W.; Berridge, J.C. Central composite design for the rapid optimisation of ruggedness and chiral
separation of amlodipine in capillary electrophoresis. Chirality 1995, 7, 226–234. [CrossRef]
49. Bechet, I.; Paques, P.; Fillet, M.; Hubert, P.; Crommen, J. Chiral separation of basic drugs by capillary zone electrophoresis with
cyclodextrin additives. Electrophoresis 1994, 15, 818–823. [CrossRef]
50. Boonkerd, S.; Detaevernier, M.R.; Vander Heyden, Y.; Vindevogel, J.; Michotte, Y. Determination of the enantiomeric purity
of dexfenfluramine by capillary electrophoresis: Use of a Plackett-Burman design for the optimization of the separation. J.
Chromatogr. A 1996, 736, 281–289. [CrossRef]
51. Varesio, E.; Gauvrit, J.-Y.; Longeray, R.; Lantéri, P.; Veuthey, J.-L. Central composite design in the chiral analysis of amphetamines
by capillary electrophoresis. Electrophoresis 1997, 18, 931–937. [CrossRef]
Molecules 2021, 26, 4681 37 of 40
52. Fanali, S.; Furlanetto, S.; Aturki, Z.; Pinzauti, S. Experimental design methodologies to optimize the CE separation of epinephrine
enantiomers. Chromatographia 1998, 48, 395–401. [CrossRef]
53. Guillaume, Y.C.; Peyrin, E. Chemometric method to optimize chiral separation of imidazole derivatives by capillary electrophore-
sis. Talanta 1999, 50, 533–540. [CrossRef]
54. Vargas, M.G.; Vander Heyden, Y.; Maftouh, M.; Massart, D.L. Rapid development of the enantiomeric separation of β-blockers by
capillary electrophoresis using an experimental design approach. J. Chromatogr. A 1999, 855, 681–693. [CrossRef]
55. Daali, Y.; Cherkaoui, S.; Christen, P.; Veuthey, J.-L. Experimental design for enantioselective separation of celiprolol by capillary
electrophoresis using sulfated β-cyclodextrin. Electrophoresis 1999, 20, 3424–3431. [CrossRef]
56. De Boer, T.; Bijma, R.; Ensing, K. Modelling of conditions for the enantiomeric separation of β2-adrenergic sympathicomimetics
by capillary electrophoresis using cyclodextrins as chiral selectors in a polyethylene glycol gel. J. Pharm. Biomed. Anal. 1999, 19,
529–537. [CrossRef]
57. Zhu, X.; Lin, B.; Jakob, A.; Epperlein, U.; Koppenhoefer, B. Optimization and parameter study for chiral separation by capillary
electrophoresis. HRC J. High. Resolut. Chromatogr. 1999, 22, 449–453. [CrossRef]
58. Perrin, C.; Vargas, M.G.; Vander Heyden, Y.; Maftouh, M.; Massart, D.L. Fast development of separation methods for the chiral
analysis of amino acid derivatives using capillary electrophoresis and experimental designs. J. Chromatogr. A 2000, 883, 249–265.
[CrossRef]
59. Gotti, R.; Furlanetto, S.; Andrisano, V.; Cavrini, V.; Pinzauti, S. Design of experiments for capillary electrophoretic enantioresolu-
tion of salbutamol using dermatan sulfate. J. Chromatogr. A 2000, 875, 411–422. [CrossRef]
60. Mateus, L.; Cherkaoui, S.; Christen, P.; Veuthey, J.-L. Enantioseparation of atropine by capillary electrophoresis using sulfated
β-cyclodextrin: Application to a plant extract. J. Chromatogr. A 2000, 868, 285–294. [CrossRef]
61. Loukas, Y.L.; Sabbah, S.; Scriba, G.K.E. Method development and validation for the chiral separation of peptides in the presence
of cyclodextrins using capillary electrophoresis and experimental design. J. Chromatogr. A 2001, 931, 141–152. [CrossRef]
62. Brunnkvist, H.; Karlberg, B.; Granelli, I. Enantiomeric separation of TAPP, H-Tyr-(D)Ala-Phe-Phe-NH2, by capillary electrophore-
sis using 18-crown-6-tetracarboxylic acid as a chiral selector. J. Chromatogr. B 2003, 793, 343–350. [CrossRef]
63. Saavedra, L.; Barbas, C. Optimization of the separation lactic acid enantiomers in body fluids by capillary electrophoresis. J.
Chromatogr. B 2002, 766, 235–242. [CrossRef]
64. Harang, V.; Tysk, M.; Westerlund, D.; Isaksson, R.; Johansson, G. A statistical experimental design to study factors affecting
enantioseparation of propranolol by capillary electrophoresis with cellobiohydrolase (Cel7A) as chiral selector. Electrophoresis
2002, 23, 2306–2319. [CrossRef]
65. Ficarra, R.; Cutroneo, P.; Aturki, Z.; Tommasini, S.; Calabrò, M.L.; Phan-Tan-Luu, R.; Fanali, S.; Ficarra, P. An experimental design
methodology applied to the enantioseparation of a non-steroidal anti-inflammatory drug candidate. J. Pharm. Biomed. Anal. 2002,
29, 989–997. [CrossRef]
66. Awadallah, B.; Schmidt, P.C.; Wahl, M.A. Quantitation of the enantiomers of ofloxacin by capillary electrophoresis in the parts
per billion concentration range for in vitro drug absorption studies. J. Chromatogr. A 2003, 988, 135–143. [CrossRef]
67. Marchesini, A.F.; Williner, M.R.; Mantovani, V.E.; Goicoechea, H.C.; Robles, J.C. Optimization of the enantioseparation of ketamine
by using capillary electrophoresis and β-carboxy-cyclodextrins. Acta Farm. Bonaer. 2004, 23, 201–205.
68. Perrin, C.; Fabre, H.; Massart, D.L.; Vander Heyden, Y. Influence of peak measurement parameters on the quality of chiral
electrophoretic separations. Electrophoresis 2003, 24, 2469–2480. [CrossRef]
69. Perrin, C.; Fabre, H.; Maftouh, M.; Massart, D.L.; Vander Heyden, Y. Robustness testing of chiral separations by capillary
electrophoresis using highly sulfated cyclodextrins. J. Chromatogr. A 2003, 1007, 165–177. [CrossRef]
70. Jimidar, M.I.; Van Ael, W.; Van Nyen, P.; Peeters, M.; Redlich, D.; De Smet, M. A screening strategy for the development of
enantiomeric separation methods in capillary electrophoresis. Electrophoresis 2004, 25, 2772–2785. [CrossRef] [PubMed]
71. Zhang, Y.-P.; Lee, K.-P.; Kim, S.-H.; Choi, S.-H.; Gopalan, A.I.; Yuan, Z.-B. Comparative study on the chiral separation of phenyl
alcohols by capillary electrophoresis and liquid chromatography. Electrophoresis 2004, 25, 2711–2719. [CrossRef]
72. Jimidar, M.I.; Vennekens, T.; Van Ael, W.; Redlich, D.; De Smet, M. Optimization and validation of an enantioselective method for
a chiral drug with eight stereoisomers in capillary electrophoresis. Electrophoresis 2004, 25, 2876–2884. [CrossRef] [PubMed]
73. Martinez-Gomez, M.A.; Villanueva-Camañas, R.M.; Sagrado, S.; Medina-Hernández, M.J. Multivariate optimization approach
for chiral resolution of drugs using human serum albumin in affinity electrokinetic chromatography-partial filling technique.
Electrophoresis 2005, 26, 4116–4126. [CrossRef]
74. Elek, J.; Mangelings, D.; Iványi, T.; Lázár, I.; Vander Heyden, Y. Enantioselective capillary electrophoretic separation of
tryptophane- and tyrosine-methylesters in a dual system with a tetra-oxadiaza-crown-ether derivative ad a cyclodextrin. J. Pharm.
Biomed. Anal. 2005, 38, 601–608. [CrossRef]
75. Zhang, Y.P.; Jun Zhang, Y.; Jun Gong, W.; Ming Wang, S.; Yong Xue, H.; Pill Lee, K. Design of experiments for capillary
electrophoretic enantioresolution of tamsulosin using sulfated-β-cyclodextrin as chiral selector. J. Liq. Chromatogr. Rel. Technol.
2007, 30, 215–234. [CrossRef]
76. Danel, C.; Chaminade, P.; Odou, P.; Bartélémy, C.; Azarzar, D.; Bonte, J.-P.; Vaccher, C. Enantioselective analysis of the antipsychotic
9-hydroxyrisperidone, main metabolite of risperidone, by chiral capillary EKC using dual CDs. Electrophoresis 2007, 28, 2683–2692.
[CrossRef]
Molecules 2021, 26, 4681 38 of 40
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